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MObjectives: To develop a method of economic
evaluation and triage for research prioritisation, before
the funding decision.
Data sources: Existing models were researched
focusing on MEDLINE, HealthSTAR, IBSS and HEED.
Review methods: Papers of primary relevance that
included a proposed model were reviewed in detail,
and their models appraised using criteria adapted from
the EUR-ASSESS project and the authors’ previous
experience. From this the PATHS model was
developed. It assumes three or more possible
alternative outcomes or scenarios in terms of research
results: ‘favourable’ to the technology being assessed,
‘unfavourable’ or ‘inconclusive’. An associated flow of
benefits or disbenefits, costs or savings is identified for
each potential research outcome depending on the
likely implementation of the results as judged by
experts. These benefits and costs are weighted and
discounted in the model to give an expected
incremental cost-effectiveness ratio (EICER). EICERS
could be estimated for any number of research areas
or proposals to inform funding prioritisation. The
model was tested and evaluated on three case studies
identified in liaison with the NHS R&D HTA
programme and the UK Medical Research Council.
These case studies were funded research projects,
where full evaluation was underway and where results
would be reported during the PATHS project. The
studies were selected to include surgery or other
invasive procedures, and non-invasive health services
projects (a fourth case study did not complete during
the course of the study). The three case studies
included randomised controlled trials of early surgery
or observation for small abdominal aortic aneurysms,
infusion protocols for adult pre-hospital care, and
postnatal midwifery support.
Results: Each of the three assessments indicated net
clinical benefit or no clinical loss of benefit, in addition
to health service cost savings in excess of the cost of
the trial. For two case studies, the value of the
proposed trial, as evaluated by the model in the
prediction, was consistent with the ex post evaluation,
thus providing positive tests of the value of the model.
In the third case meaningful ex post analysis was not
possible as very poor compliance with the trial
protocol (indicated in the ex ante evaluation) seriously
undermined its conclusions. During the study, at the
request of the UK HTA programme, the model was
also applied to a funding request for a large randomised
trial of β-interferon for multiple sclerosis treatment.
Conclusion: The PATHS model has a useful part to
play in the research prioritisation process. Its strengths
lie in its emphasis on the impact of research results on
policy and practice (the keystone for NHS research)
and net effects on health benefits and costs. It assesses
the cost-effectiveness of the research and may identify
ways to enhance the research design, endpoints
relevant to implementation, analytical methods and
dissemination. Further research is recommended to
investigate the scope for synthesising the strengths of
the PATHS model with other approaches including
value of information; to compare ex ante and
immediate ex post assessments of implementation with
long term follow-up of actual implementation; and to
assess the robustness of such approaches to the choice
and number of experts used.
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Ex ante: before the assessment.
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Glossary and list of abbreviations
List of abbreviations
AAA abdominal aortic aneurysm
A&E accident and emergency
CI confidence interval
CMSW community midwifery support 
worker
DRG diagnosis related group
EICER expected incremental cost-
effectiveness ratio
ENBR expected net benefits of the 
research
EVPI expected value of perfect 
information
EVSI expected value of sample information
GHP General Health Perception (of the 
SF-36)
HEED Health Economic Evaluation
Database
HRT hormone replacement therapy
IBSS International Bibliography of the
Social Sciences
INF-β beta-interferon
IOM Institute of Medicine
ITU intensive therapy unit
MOS medical outcomes study
MRC UK Medical Research Council
MS multiple sclerosis
NICE National Institute for Clinical
Excellence
OR odds ratio
PATHS Preliminary Assessment of
Technology for Health Services
QALY quality-adjusted life year
RCT randomised controlled trial
R&D research and development
RR-MS relapsing remitting stage of multiple
sclerosis
SF-36 Short Form 36
SP-MS secondary progressive stage of
multiple sclerosis
TAPSS Technology Assessment Priority
Setting System
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Background
Organisations funding health technology
assessment face problems of prioritisation, and
some method of estimating potential returns to
research is needed if limited funds are to be used
cost-effectively. Most funding bodies, such as the
UK NHS R&D HTA programme and the Medical
Research Council (MRC), use criteria-based
systems that do not include explicit calculation of
cost-effectiveness and do not formally estimate
returns to a research project.
Objectives
The Preliminary Assessment of Technology for
Health Services (PATHS) study aimed to develop a
method of economic evaluation and triage at the
stage of research prioritisation, before the funding
decision. It is for use either at the stage of
deciding on an area of research for funding, or at
the specific proposal stage, or both, and assesses
whether the additional information from an
assessment will justify its cost in terms of the likely
health gain and costs resulting from its impact on
the use of that technology, and if so what priority
should be given to that assessment. 
Method
Existing methods were reviewed against formal
criteria and a model was developed that
synthesised the best aspects of existing models.
The approach used data from existing sources and
judgements from experts, concerning possible
clinical outcomes of the proposed assessment. 
The PATHS model assumes three or more
alternative outcomes or scenarios in terms of the
research ‘results’: ‘favourable’, ‘unfavourable’ and
‘inconclusive’ outcomes. An associated flow of
benefits or disbenefits, costs or savings is
identified for each outcome depending on likely
implementation of the results as judged by
experts. These benefits and costs are discounted in
the model to give an expected incremental cost-
effectiveness ratio (EICER). EICERs could be
estimated for any number of research areas or
proposals to inform funding prioritisation. By
comparing the EICERs across research technology
areas or proposals within one particular area, and
the cost and effects of continuing with the current
provision, a funding body could allocate funds to
provide more efficient returns to research. 
Data for the model
The model is straightforward and transparent, and
does not require major data collection. Data
include estimates of benefits to patients, costs of
the technology, level of its use in the absence of
the proposed assessment (the counterfactual),
likely developments in the technology during the
period of evaluation, and expected changes in use
of the technology given alternative outcomes of
the assessment. Alternative values can be
incorporated for net costs, benefits and
probabilities for each scenario, and the expected
level of the implementation can be adjusted,
allowing the evaluation to reflect likely impact on
practice as a result of reduction in uncertainty.
Where available, empirical data are used, with
gaps filled by expert opinion. The experts may
include clinical, health economic and purchaser
expertise to represent relevant decision-makers
and to triangulate the estimates.
Testing the model
The model was tested and evaluated on three case
studies identified in liaison with the NHS R&D
HTA programme and the MRC. These case
studies were funded research projects, where full
evaluation was underway and where results would
be reported during the PATHS project. Two MRC-
and two HTA-funded studies were selected to
include surgery or other invasive procedures and
non-invasive health services research projects; one
case did not complete during the course of the
study. The three case studies included randomised
controlled trials of postnatal midwifery support,
infusion protocols in adult pre-hospital care, and
early surgery or observation for small abdominal
aortic aneurysms.
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Executive summaryFor two case studies, the value of the proposed
trial, as evaluated by the model in the ex ante
prediction, was consistent with the ex post
evaluation, thus providing positive tests of the
model. Each of these assessments indicated net
clinical benefit or no clinical loss of benefits, in
addition to health services cost savings in excess of
the trial cost. In the third case meaningful ex post
analysis was impossible, as very poor compliance
with the trial protocol seriously undermined its
conclusions. 
Live application of model
During the course of the project the investigators
were asked to apply the model to an application
for funding a large randomised trial of β-
interferon for multiple sclerosis treatment,
submitted to the UK HTA programme. The results
of this analysis illustrate further the use of the
model. 
Conclusions
The NHS R&D programme sets relevance to the
improvement of health and health services as the
keystone for research prioritisation. To assess the
effects on implementation the baseline level of use
must be known, but this is rarely provided. Survey
data may be considered an essential adjunct to a
literature review, to provide a basis for assessing
the relevance and potential importance of a health
technology assessment, as information on the
current use of a technology, and its expected
trajectory, is essential to the assessment of
payback. The implications are different for a new
technology that would be adopted only if good
evidence were provided, compared with a
technology that, despite lack of good evidence, is
already in use. A large part of the payback in the
cases considered was due to an expectation that
the research would lead to a reduction in the use of
the technology were it proved to have low benefit.
Negative results may produce high payback. An
essential element of the evaluation is the explicit
assessment of the counterfactual, and
consideration of the length of time over which the
research may influence policy. This will depend on
emerging information and changes to the
technology or its competitors. In an area of rapid
technological change, the policy relevance of a
piece of research may be transient.
In conclusion, the PATHS model has a useful part
to play in the research prioritisation process
alongside existing criteria; its strength lies in its
emphasis on impacts on policy and practice, and
net effects on health benefits and costs. It assesses
the cost-effectiveness of the research and may
identify ways to enhance the research design, end-
points, analytical methods and dissemination.
Suggestions for HTA funders
Applications of the model need to be conducted
by competent and impartial evaluators and to be
transparent. The model was tested here on
primary research, but it could be applied to any
form of research, including secondary analysis and
reviews. Such an assessment is likely to cost £1000
to £4000, possibly more for a large or complex
project. This is a small proportion of the typical
research cost and should give good returns by
excluding low-return proposals and improving the
policy relevance of others. HTA funders should
consider formal analysis of potential payback in
the later stages of evaluation for projects costing,
say, over £250,000. The scale and intensity of the
exercise could be varied to reflect the cost, policy
importance and contentiousness of the proposal. 
Recommendations for further
research
Other developments in the literature have
occurred in parallel with this work. Further
research is needed:
  to investigate how to synthesise the strengths of
the value of information and the PATHS
approaches
  to compare ex ante and immediate ex post
assessment of implementation with long-term
follow-up of actual implementation 
  to assess the robustness of such approaches to
the choice and number of experts used.
Executive summary
xA
ll organisations funding health technology
assessments (HTAs) are faced with problems of
prioritisation.1,2 The continuing development of
healthcare technologies has increased the number
of technologies for potential assessment, while the
increased demand for evidence to inform health-
service practice and clinical decision-making has
resulted in the rapid growth of health technology
assessment programmes and proposed
assessments. The funds available limit what can be
evaluated: in 1997, approximately 1800 topics
were proposed as candidates for assessment under
the UK NHS R&D HTA programme; only 2%
secured research funds in that funding cycle.3 To
inform this decision process health technology
assessment organisations need to assess potential
returns to their limited research funds and apply
cost-effectiveness to the choice of trials as well as
to the actual use of the technologies.
The EUR-ASSESS project (an international group
designed to stimulate and coordinate
developments in health technology assessment in
Europe and to improve decision-making
concerning adoption and use of health technology)
produced a set of guidelines for the prioritisation
of HTA projects.4 These guidelines suggest that:
  it should be clear to all involved in a health
technology assessment programme how
priorities are identified
  there should be agreement regarding the
approach, method and criteria for assessment
between those responsible for priority setting
  the approach should reflect the goals of the
programme and the resources available
  the aim of the priority setting process should be
to ensure that the priorities reflect the likely
costs and benefits of the possible assessments 
  where possible, the method for priority setting
should allow possible assessment to be rated in
a systematic way against explicit criteria.
Health technology assessment organisations such
as the UK NHS R&D HTA programme and the
Medical Research Council (MRC) currently
employ a criteria-based system for the
prioritisation of research projects.1,2 These systems
do not include explicit calculation of the cost-
effectiveness of undertaking research. Those
advising research funding decisions are typically
given a checklist of criteria (e.g. Would the project
lead to a reduction in uncertainty? Are the costs
justified? Are the objectives clearly stated?) against
which research projects are judged. Funding
bodies weigh likely costs and benefits, but usually
in general and qualitative terms. They rarely
attempt to estimate systematically the cost-
effectiveness of undertaking a research project. If
methods were available to provide ready and
reliable quantitative estimates of the likely returns
from competing uses of their resources, health
technology assessment funding organisations
would have greater reassurance as to the
appropriateness of their funding decisions.
The PATHS study
For ease of reference, this study is called the PATHS
(Preliminary Assessment of Technologies for Health
Services) study. It was set up to develop a
practicable method for economic evaluation and
triage at the stage of prioritisation of health
technology assessment either at the stage of
considering general topics or at the stage of specific
proposals, but before the funding decisions.5
The study aims to clarify whether it is possible 
ex ante to identify whether the costs of a health
technology assessment are justified in terms of its
likely implication for adoption or reduced use of
that technology, and how to prioritise those
projects that appear to be justified. Existing
methodological approaches are reviewed and a
formal methodology is synthesised. This model is
tested with the aid of expert panels in three case
studies of evaluations funded and underway as the
research commenced and expected to report
during the course of the project.
The proposed approach requires estimates of
parameters from existing data and professional
judgements concerning:
  examples of possible clinical outcomes of the
proposed assessment
Health Technology Assessment 2003; Vol. 7: No. 20
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Chapter 1
Background: health technology assessment 
prioritisation  benefits to patients from these clinical outcomes
  estimates of costs of the technology to be
assessed
  the direction of policy or use of the technology
in the absence of the proposed full evaluation
  likely developments in the technology during
the lifetime of the assessment
  appropriate policy changes in use of the
technology for possible clinical outcomes of the
assessment
  actual likely policy changes.
These parameter estimates need to be made with
as full information as possible. Some estimates
may be available from existing data, but some will
not be. In this study a small expert panel was
formed for each case study, typically consisting of
two clinical or scientific experts in the field, a
health economist and a ‘purchaser’ or decision-
maker, all of whom would be independent of the
proposal. Possible options for the parameters were
discussed with each expert and these assumptions
fed into the model with cost and benefit data for
different outcomes, the cost of the technology
assessment and an agreed period of payback.
Results from this ‘ex ante’ evaluation were tested
against the actual outcomes from the technology
assessments and the implications for policy and
practice discussed with the panels. By focusing on
a sample of funded technology assessments, the
aim was to obtain an indication of whether such a
formal evaluation process might have added useful
information to the funding process and possibly
have led to a different decision.
Background: health technology assessment prioritisation
2Introduction
In recent years the evaluation of the returns to
public sector investment in research and
development has moved up the policy agenda.6–8
The reasons for this include the need for increased
accountability, improved cost-effectiveness of
research and an improved information base for
decisions about allocating research funds. Much of
the initial work and most of the pioneering
current work has been developing methodology
and applying it retrospectively to completed
research; that is, looking at payback.9,10 These
concerns for accountability and cost-effectiveness
have extended the discussions to
management6,11,12 and to monitoring.13–15 Work
on ex ante assessments, attempting to predict
returns to research before funding has been
granted and the research undertaken, has been
rare, although there is increasing interest in the
role that economic analysis can play in the
prioritisation of research funding. 
Methods
Search methods
The primary aim of this literature review was to
identify relevant published studies that proposed a
conceptual/theoretical model for relating
prospectively the costs, at any level, of
undertaking a health-services research project (or
programme) with the projected benefits (however
measured) of that research, which could be used to
prioritise non-commercial research topics or
proposals. The secondary aim was to note more
general papers concerning the assessment of
payback to research, which provide context and
additional ideas for the discussion below. 
Given the difficulties of undertaking systematic
searches on methodological issues, particularly as
here, where the known relevant literature uses a
variety of non-specific terminology, search
strategies were developed to achieve higher
sensitivity rather than specificity. The strategy
used a variety of possible search terms, to
maximise the yield of relevant studies. The search
focused on the following electronic bibliographic
databases: MEDLINE, HealthSTAR and IBSS
(International Bibliography of the Social Sciences).
The search was limited to English language
journals only. Articles identified by the searches
were reviewed for relevance by two of the team
(GH and JT) on the basis of title (and abstract
where available). If relevant, or in the case of
doubt, full articles were obtained and reviewed. In
addition, reference lists of relevant articles were
scanned for further possibly relevant studies. 
The initial search was carried out in May 1998,
with a subsequent updating search of the literature
in January 2002 (with a review conducted in an
equivalent manner by MB and JT) to inform the
concluding chapter of parallel developments in
the literature. The updating search was extended
to cover the Health Economic Evaluation Database
(HEED): this did not identify any papers of
primary relevance that had been missed by the
original search in 1998. 
Further details of the specific search terms are
given in Appendix 1.
Appraisal criteria
Papers of primary relevance that included a
proposed model were reviewed in detail, and their
models appraised using criteria adapted from the
EUR-ASSESS project and previous experience of
the authors.4,5,16
The appraisal criteria used were as follows.
  Is the aim of the model clear? Is it concerned
with identifying technologies for assessment or
for prioritising individual trials, or both?
  Does the model consider alternative outcomes
of a trial, and the uncertainty surrounding the
outcomes in a probabilistic framework?
  Does the model consider the counterfactual –
what would happen if the trial were not 
funded?
  Does the model consider the implications of the
likely implementation of an intervention
following the reporting of the trial’s conclusions?
  Could the model be operationalised (i.e. would
a data source be available)?
  Are other forms of payback to the research
considered? In particular, are weights assigned
to a range of potential benefits to research?
Health Technology Assessment 2003; Vol. 7: No. 20
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Chapter 2
Review of the literature  Could the model be used within an iterative
economic evaluation framework, using data
from earlier stages and also informing later
stages?
  Is the assessment process transparent and easily
interpretable by a research funding body and
potential funding applicants?
  Are the uncertainty and subjectivity related to
the data collection and modelling process
considered?
  Is the process likely to be efficient? In
particular, would the process itself consume
sizeable resources such as researchers’ time and
costs of data collection?
  Could the process be flexible to adjust to
different scales of research?
  Could the model accommodate alternative
outcome measures of a trial if necessary?
  Could the model accommodate analysis of
particular subgroups of patients?
Results
The searches identified 799 possible separate
articles. The full text of 26 of these was obtained.
From the full texts, it emerged that ten papers
related to seven published models that fulfilled the
primary requirements for inclusion (a proposed
model of research assessment or prioritisation, or
a quantitative example of assessing the benefits of
a research project in relation to costs).16–25 Other
papers did not include an appropriate model but
some had relevant material that informed the
analysis and critique of the models, and are
referred to subsequently in discussion. 
The seven major models are described in brief
below and then appraised using the predetermined
criteria.
1. Claxton and Posnett17
This model assesses the value of new information
using a Bayesian approach. The model
incorporates the expected value of perfect
information (EVPI) and the expected value of
sample information (EVSI), expressed in monetary
units. It is a ‘two-hurdle’ model designed to make
an assessment first at the technology level and
then at the specific research proposal level. The
EVPI is used first to assess whether a reduction in
the uncertainty surrounding a technology area
would be valuable. The criterion set by Claxton
and Posnett is for the EVPI to exceed the fixed
costs of the research. To ensure that the design of
a specific trial is cost-effective when conducted at
optimal size, it must clear the second hurdle, that
the expected net benefits of the research (ENBR)
are greater than zero, at optimal sample size. 
2. Detsky18–20
This model, first set out by Detsky in 1985, relates
the impact of a trial, with given power and
significance level, to the distribution of the risk
reduction of the problem under consideration.18
For example, this could be in terms of the number
of people currently dying per year following
treatment with a traditional therapy compared
with the situation following the new assessed
therapy. By relating the risk reduction to the trial
cost, he estimates the cost-effectiveness ratio of the
research, assuming 100% implementation
following the conclusion of the trial and a
theoretical distribution of both risk and costs. His
subsequent papers apply this model
(retrospectively) to seven major randomised
controlled trials (RCTs) that had been recently
completed and reported.19,20
3. Drummond and colleagues21
This decision-analytical model was developed to
assess retrospectively the returns to a specific
applied research project, the Diabetic Retinopathy
Study, funded by the National Eye Institute from
1972 to 1981. Adjustments can be made to the
probabilities within the decision tree (the relative
probabilities of whether a patient has diabetic
retinopathy before and after the trial) and to the
size of the population benefiting from the
intervention following the trial, as well as the
benefits they might receive and the costs of the
implementation. Although applied retrospectively
here, the same framework could be used
prospectively.
4. Eddy22
The Technology Assessment Priority Setting
System (TAPSS) models the effect of a range of
factors on costs and benefits resulting from a
technology assessment. It is a decision-analytical
model and factors include the number of potential
candidates for the intervention under evaluation,
the probability that the assessment will arrive at a
particular result, the implementation following
that result and the population likely to receive the
technology. The model systematically allows for
variation in these key variables, and the
uncertainty in the estimation of the variables. The
model can incorporate different possible outcomes
and can combine alternative results
probabilistically into a single figure. It forms the
basis of a number of later decision-analytical
models (e.g. Townsend and Buxton16) and was an
important influence on the prioritisation process
developed for the US Agency for Health Care
Policy and Research by a Committee of the
Institute of Medicine in 1990 and 1992.1,26
Review of the literature
45. Phelps and Parente23,24
Phelps and Parente developed an uncertainty
model that estimates the implied value of
assessing a technology based on the unexplained
variation in medical expenditure. It presented an
application comparing procedures based on data
on variations in expenditure between different
counties within New York State.23 The model
assumes that all variation in expenditure not
explained by demographic or socioeconomic
factors is due to the uncertainty about the
outcome of the intervention. It makes a further
assumption that the ‘correct’ level of expenditure
is approximated by the adjusted mean level of
expenditure, and that there is a fixed elasticity of
demand for all health technologies. Welfare losses
associated with these unexplained variations in
expenditure are estimated and compared across
diagnosis related groups (DRGs) to identify the
estimated highest payoff from potential research
spending. The model is focused at the technology
rather than the research proposal level. It is an
imaginative and operational concept, but is
limited both by its strong assumptions and by its
broadbrush approach of associating just one
technology assessment with each DRG. Small
corrections to the computations in the original
paper were reported subsequently by Phelps and
Mooney.24
6. Townsend and Buxton16
This model, which also uses decision analysis, was
developed and applied to a proposed trial of the
long-term use of hormone replacement therapy
(HRT). It is an ex ante model for use at technology
or project level and explicitly considers three (or
more) broad scenarios of potential trial outcomes:
positive, negative and inconclusive. Changes in
the long-term use of the technology are predicted
for each outcome scenario, and the net effects of
these changes estimated in terms of costs and
benefits. Discounted costs and benefits are
weighted to obtain estimates of the overall cost-
effectiveness of the proposed trial. The authors
were able to draw on detailed empirical data and
published estimates of the short- and long-term
benefits of HRT. For other technologies, such
detail might not always be available, but the
authors argue that expert opinion could be used
to provide best estimates. An application is given
in the annex at the end of this chapter.
7. Weinstein25
This, the earliest of the models, focused on a
specific choice between research on a bioassay for
a potentially carcinogenic, but widely used,
chemical and a prospective study of the cancer-
reducing effects of dietary β-carotene. It provides
a generalised analytical framework and a brief
summary of somewhat simplified applications of
that framework to the specific contexts. Essentially,
it is based on standard principles of decision
analysis and cost-effectiveness analysis, in a model
that recognises the inherent uncertainty and (at
least in principle) a series of possible outcomes
from the research, each assigned a prior
probability. It explicitly recognises the need to
make a judgement about the extent to which
policy and/or practice will follow the results of the
research and so the extent to which potential
benefits will be achieved. Its conceptual framework
has been broadly adopted (apparently without
specific recognition) by Detsky, Eddy, Drummond
and colleagues, and Townsend and Buxton, and it
also provides an early reference to the EVPI
developed by Claxton and Posnett.
In Table 1 the seven models are appraised against
the set criteria given above.
Three of the papers identified in the search
focused on the limited issue of determining the
appropriate sample size for and design of studies,
in some cases linking the strength of evidence to
likely impact.27–29 The issues these raised are
important, and were noted in our thinking about
the formal models and their use. 
Commentary
A number of issues arose from reviewing the
papers. Although there was a wide literature
alluding to the issue of prioritisation, considering
the process by which research funds are allocated
or addressing the effect of trial design
(particularly sample size) on the likely impact of
the study, the search identified only seven models
that aimed to determine systematically whether a
research area or proposal was likely to be a cost-
effective investment. 
Aims of the models, their methods and
levels of information
The criteria used to assess the models are based
on how practical they are in terms of effectiveness
and efficiency for general use. In general, the
models had similar aims, namely to assess the
‘value’ of undertaking a particular piece of health-
services research or health technology assessment
and, although the precise methods used vary in
each case, there is a great deal of similarity (not
explicitly recognised or acknowledged and
probably independently developed) in the papers.
Health Technology Assessment 2003; Vol. 7: No. 20
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TABLE 1 Appraisal of the seven models
Claxton and  Detsky (1985,  Drummond et al. Eddy  (1989)22 Phelps and Parente  Townsend and  Weinstein (1983)25
Posnett (1996)17 1989, 1990)18–20 (1992)21 (1992)23 and Buxton  (1997)16
Phelps and Mooney 
(1992)24
Are the aims of
the model clear?
Is it concerned
with identifying
technologies for
assessment or for
prioritising
individual trials, or
both?
Yes. The model’s aim
is to test the
efficiency of a trial
design and promote
consistency in
decision-making and
priority setting
between research
and service provision
Yes. The model
relates the cost of a
trial to its size and to
clinically important
benefits identified in
the trial, to assess the
marginal productivity
of research funding,
when expanding or
contracting trial size
Yes. The objective is
to develop and test a
methodology for
assessing the social
costs and benefit of
research. It is
designed to consider
prospectively
whether a research
project should be
funded
Yes. The model
developed was ‘a
simple framework
and quantitative
method for
estimating the value
of assessing different
technologies’. It
considers a proposed
assessment and
evaluates how it will
affect health and
economic outcomes
Yes. It uses the
unexplained variation
in medical
expenditure by DRG
between New York
counties, to estimate
an implicit value of
assessing technology,
to that related DRG
Yes. It develops a
methodology for 
ex ante evaluation of
proposed technology
assessment,
comparing net costs
and benefits from use
of the technology
following an
assessment’s
conclusion with the
likely practice in the
absence of the
assessment
Yes. The paper sets
out a quantitative
approach to setting
priorities between
competing uses of
research funds using
examples relating to
cancer. It uses a cost-
effectiveness
framework to assess
cost per cancer
death/cost per life
year from specific
proposed trials
Does the model
include alternative
outcomes of a
trial?
Yes, to an extent.
The model compares
the cost of a trial
with the expected
net benefits for
different sample
sizes. Alternative
outcomes are
incorporated in the
determination of the
expected benefits
Yes. To calculate the
power of the trial,
the model uses an
expected level of risk
reduction, taking all
possible risk
reductions (–100%
to +100%) into
account by weighting
them with the
probability that each
outcome will occur
Yes. The model is
constructed using a
decision-theoretic
approach, with the
alternative outcomes
of the trial
represented by the
probabilities assigned
to the different
events with
sensitivity analysis
applied to these
probabilities
Yes, the alternative
conclusions of the
assessment are
reflected in the range
of delta results
selected for the
assessment. For each
delta result (the
result of an
assessment that can
potentially change
the use of a
technology) a
probability is
estimated that
reflects the likelihood
that the assessment
will reach that delta
result
No. There is a single
value for each DRG
Yes. Alternative
outcomes are
considered explicitly,
with positive,
negative and
inconclusive
outcomes defined in
terms of varying
health gains or losses
and weighted with
the probabilities of
the trial reaching
those outcomes
The general model
allows for a range of
research outcomes
(in terms of levels of
effect), although this
potential is not used
in the cases
presented in the
paper. It does use a
prior probability of
the effect
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TABLE 1 Appraisal of the seven models (cont’d)
Claxton and  Detsky (1985,  Drummond et al. Eddy  (1989)22 Phelps and Parente  Townsend and  Weinstein (1983)25
Posnett (1996)17 1989, 1990)18–20 (1992)21 (1992)23 and Buxton  (1997)16
Phelps and Mooney 
(1992)24
Can the model be
used within an
iterative economic
evaluation
framework, using
data from earlier
stages and also
informing later
stages? i.e. at
technology and
project level?
Possibly. The
calculation of the
EVSI and the EVPI
may be of limited
value in the later
stages of economic
evaluation
Possibly for trials of
different sample size
Potentially by
adaptation although
developed for a
specific trial
Potentially, as the
detailed calculations
involved in the
TAPSS model would
be of benefit in
identifying important
subgroups for specific
analyses during later
stages of the
assessment
No, as it is a specific
macro model
Yes. Easily adaptable
to either stage
Possibly, although
conceptualised in
terms of a trial (a
‘test’ of a hypothesis)
with specific
sensitivity and
specificity
Is the process
transparent and
easily
interpretable by a
research funding
body and funding
applicants?
Not easily. It is a
theoretical model,
using techniques and
concepts not easily
interpreted by
potential research
applicants
Not easily. The
concept of the prior
distribution of the
risk reduction is
complex and
subjective, and may
not be fully
understood
Yes. The decision-
analytical approach
clearly shows the
processes of the
evaluation, the
assumptions made
and what adjustments
have been made
Uncertain, as the
model involves the
interaction between
many factors. The
calculation may not
be easily understood
No. As a broad field
methodology with
strong assumptions
about methodology
and interpretation it
is neither transparent
nor intended for use
at project level
The process is
transparent and fairly
easy to interpret
The published account
is rather brief and
lacks transparency,
but it could easily be
presented in greater
detail, resulting in
greater transparency
and interpretability
Does the model
consider the
counterfactual –
what would
happen if the trial
were not to be
funded?
Not explicitly No Yes No The methodology
centres on local
practice moving
directly to current
average
Yes Does not specifically
allow for
counterfactual change
compared with
current position
Does the model
consider the likely
implementation of
the intervention
following the
reporting of the
trial’s conclusions?
Not explicitly No Yes Yes It is implied to be
100% immediately
Yes Yes. It makes a
specific judgement as
to the extent to
which the desired
change would occur
continued
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TABLE 1 Appraisal of the seven models (cont’d)
Claxton and  Detsky (1985,  Drummond et al. Eddy  (1989)22 Phelps and Parente  Townsend and  Weinstein (1983)25
Posnett (1996)17 1989, 1990)18–20 (1992)21 (1992)23 and Buxton  (1997)16
Phelps and Mooney 
(1992)24
Is there a data
source for the
model to be
operationalised?
Theoretical mode.
No example used
Published literature Published literature
and expert opinion
Estimated by author Published literature
and estimates based
on existing US county
data
Published literature
and author estimates
Published literature
and subjective
estimates by author
Are other forms
of payback
considered? If so,
what and how?
Are weights
assigned to
different potential
benefits to
research?
Other forms of
payback are not
explicitly considered.
Benefits are based on
patient utilities,
converted into
population benefits
No No. Health gains only No, but model can
be re-estimated using
other outcomes
No No No
Are the
uncertainty and
subjectivity
related to the data
collection and
modelling process
considered?
Not explicitly,
although the EVPI
could be
recalculated, with
adjustments in the
probabilistic
framework
Yes, through
sensitivity analysis
around the prior
distribution of the
risk reduction and
the power curve
Yes, through
sensitivity analysis in
calculating the cost-
effectiveness ratios
The model could be
recalculated using
different values for
the variables
No, although it could
be introduced
To an extent, through
adjusting the different
factors involved
following a trial’s
conclusion
Yes, to some degree
through sensitivity
analysis
Is the process
likely to be
efficient? In
particular, would
the process itself
consume sizeable
resources such as
researchers’ time,
costs of data
collection?
Uncertain. Complex
calculations
Process is relatively
simple, but subject to
the interpretation of
the prior distribution
Modelling exercise
would be relatively
straightforward
The data required to
calculate the result
require either
estimation or
resource-intensive
collection
Interesting approach,
but the categories
are probably too
broad to be useful.
Process relatively
simple and based on
existing data
If data or informed
opinion available,
then yes. Costs could
vary according to the
level of detail used
Process is relatively
simple and allows for
use of informed
opinion
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TABLE 1 Appraisal of the seven models (cont’d)
Claxton and  Detsky (1985,  Drummond et al. Eddy  (1989)22 Phelps and Parente  Townsend and  Weinstein (1983)25
Posnett (1996)17 1989, 1990)18–20 (1992)21 (1992)23 and Buxton  (1997)16
Phelps and Mooney 
(1992)24
Could the process
be flexible to
adjust to different
scales of research?
Uncertain: not
applied to data
Yes: the model was
applied
retrospectively to a
number of trials
ranging in cost from
$78,000 to $150,000
Yes, although the
application was to
the NEI Diabetic
Retinopathy Study,
the cost of which
was $10.5 million.
For an application to
a smaller trial, the
sensitivity analysis
would need to be
more precise
Data on small trials
unlikely to be
available to the
extent required by
the TAPSS model
No Potentially more
applicable to big
trials, such as the
proposed HRT trial
to which the model
has been applied.
Implementation
following trial
outcomes will
require precise
sensitivity analysis for
smaller trials
Does not obviously
lend itself to small
studies
Can the model
accommodate
alternative
outcome
measures of the
trial, if necessary?
It can accommodate
a number of patient-
based outcomes, as
the effectiveness is
based around
patients’ utilities.
However, it may be
difficult to include
other forms of
benefits
Difficult, as
effectiveness is based
on change in risk
reduction, requiring
one health-related
outcome
Use of QALYs is
possible, which
combine a number of
health-related
outcomes. However,
other forms of
benefits are not
considered
Yes, but the model
would need to be
recalculated and the
results combined
with some weighting
procedure
All outcomes
subsumed as
potential benefits are
based on the
assumed welfare
losses from deviation
from current average
practice
Yes, application can
use QALYs,
combining a number
of health outcomes
Example estimates
costs per cancer
death avoided, per
life saved, and per
year of life saved
Can the model
accommodate 
the analysis of
particular
subgroups of
patients?
Not explicitly
considered, but
would be possible
Not explicitly
considered, but
would be possible
Yes, within the
decision-analysis
framework
Yes No, it is relevant to
average county
practice
Not explicitly
considered, but
would be possible
Not explicitly
considered, but
would be possibleIt could be argued that conceptually all the
models can be logically linked back to that of
Weinstein, except that of Phelps and Parente
which builds on the work relating to local and
regional variation in the use of technologies
pioneered by Wennberg.30 This latter approach
can only be used in relation to research to reduce
uncertainty concerning existing technologies, and
the quantification of benefit rests on the heroic
assumption that on average current practice is
desirable. All the other more satisfactory methods
are some variant of a decision-analytical approach,
seemingly first set out by Weinstein, sometimes
with the costs and benefits for each trial outcome
and the subsequent implementation pattern
combined probabilistically. Such an approach has
the advantages that the benefits of an assessment
are clearly defined in terms of the effect of the
health technology assessment on practice, and as a
result of health outcomes. 
Those models that require a formal calculation of
the expected value of the information provided
from an assessment, such as Claxton and
Posnett,17 pose two major problems. The level of
information available before the trial would need
to be combined into a prior distribution, for
example, of the perceived mortality risk reduction
of undergoing a surgical procedure; this may be
difficult to carry out and is not likely to be
transparent. Also, some of these models attempt to
convert the value of increased information into
financial terms; the problems of this have long
been recognised. As Buxton and Hanney argue,
such problems are “probably no more readily
soluble for research payback assessment than for
the assessment of the interventions themselves.”10
Staged approach
A major test of the efficiency of a model is likely to
be the ease with which the model could fit into a
health technology assessment funding
organisation’s existing processes of funding
allocation. Sculpher and co-workers described the
possibility of using economic evaluation iteratively
as part of the health technology assessment
process,31 possibly with earlier preliminary analysis
at technology level being used to inform later
decisions, at project level or in identifying
subgroups on which the full evaluation might
concentrate. The earlier stages of the iterative
process involve the prioritisation of technologies.
Data collected for analysis at this stage might be
used productively at a later stage. Buxton and
Hanney9 described a three-stage approach to the
prioritisation in terms of estimating the payback
from research. The first two stages (theoretical
potential payback and expected potential payback)
consider topics or technologies, while the third
stage (likely realisable payback) considers specific
research proposals designed to reduce specific
elements of uncertainty surrounding the
technology that had been identified in the
previous two stages. The more theoretical models
may not have the requisite characteristics to satisfy
this overall three-stage approach. 
Dealing with uncertainty
It is uncertainty that prompts the initial demand
for some form of health technology
assessment.32–34 The nature of this uncertainty is
most appropriately investigated at the technology
stage, to see how detrimental it is and, if
ameliorated, whether net benefits might accrue.
The extent of the uncertainty is important, and
other things being equal, the more ‘unknowns’,
the higher the likely cost of the necessary specific
research projects. The cost of a specific proposal
will depend on what it is we are uncertain about.
Uncertainty may surround the cost of a particular
intervention, the effectiveness of a particular
intervention, or both the costs and the
effectiveness. Identification of the nature and
extent of the uncertainty will influence both the
research proposal and the full evaluation stages.
There will also be uncertainty and some degree of
subjectivity about implementation; that is, how the
research results may influence practice. This will
depend on the effectiveness of existing means of
dissemination of information among practitioners,
commissioners and policy makers, and on the
professional and institutional rigidities. There will
also be uncertainty surrounding the data used; the
models could be recalculated with sensitivity
analysis.
Models, such as those of Drummond and
colleagues21 and Townsend and Buxton,16 that use
direct health outcomes within a probabilistic,
decision-analytical framework, and clear measures
of the proportion of the population likely to
benefit from the intervention following the trial’s
conclusion, are likely to be able to handle
uncertainty most systematically. The more
‘theoretical’ approach of Claxton and Posnett17
does not focus attention on the uncertainty
surrounding variables such as the extent of
implementation. In our context, the major
criterion of the efficiency of the model is how
likely it will be able to influence decisions made by
a research-funding organisation. This may raise
problems for models using concepts that may
appear abstract to potential funders or funding
applicants.
Review of the literature
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considering the counterfactual
To consider the incremental effects of the trial on
subsequent practice, a model needs to include
what practice would be were the trial not funded.
It may not be sufficient to assume that current
practice continues. Many assessments take place
against a background of changing practice. The
incremental effects of the trial relating to changes
in practice need to be explicitly accounted for in
terms of health gains. A trial that finds in favour
of an intervention that would have been
introduced or continued in use anyway, but would
not have prevented its adoption had it found
against the intervention, is clearly unnecessary. 
The likely impact on practitioners’
behaviour
We take the view that given that the ultimate
purpose of health technology assessment is
improved healthcare, the outcome needs to
include the implications of the resultant likely use
of the technology, and so it would be insufficient
for outcomes to be expressed in terms of the
reduction in uncertainty alone; that is, an
assessment’s health-related benefits must consider
the extent to which an assessment’s conclusions
will affect health-service practitioners’ subsequent
behaviour. A number of models, including those of
Detsky and Phelps and Parente, assume full
implementation of the intervention following the
report of a trial’s findings. Organisational barriers,
ineffective information dissemination and poor
management of change are likely to operate at
varying levels, and prevent or delay the immediate
adoption of the more effective or cost-effective
technology or intervention in some organisations.
A realistic model would allow some means of
assessing the extent of the likely adoption of the
more cost-effective technology, perhaps through
the use of expert opinion.
Non-health benefits
A conflict arises between the multidimensional
nature of payback from health-services research
and the need for a precise quantitative model.
Buxton and Hanney9 identified five different
categories of potential benefits from health-
services research: knowledge benefits, benefits to
future research, political and administrative
benefits, health benefits and broader economic
benefits. Health technology assessment
organisations, according to their objectives and
sources of funding, may place different emphases
on these, and it is possible to argue that a model
designed to prioritise research projects should
relate these potential benefits from research
directly to the resource implications of
undertaking the research. As stated earlier, such a
model would require estimates of the relative
importance of each form of benefit. For some
health technology assessment programmes, it is
clear that the prime motivation is to improve the
cost-effectiveness of the health system. Any other
form of benefit or payback, albeit important,
would be considered secondary. Therefore,
preliminary cost-effectiveness studies using
quantitative models to evaluate a research
proposal have understandably concentrated on the
health benefits, to reduce subjectivity in terms of
weighting alternative forms of payback from
research. Other forms of benefits, however, should
not be ignored and, whereas the majority of
applications of the models concentrate on the
health benefits, minor modifications of models
such as TAPSS and the other decision-analytical
models would allow other forms of payback to be
assessed, and non-health benefits could and
should be considered alongside the model. 
Resource requirements to
operationalise the model
Central to all these considerations is the availability
of data required to operationalise a model. A
number of models rely on existing published data.
Frequently, given the inherent uncertainty,
appropriate data may not be available and a
surrogate alternative, such as expert opinion, may
be necessary. Data requirements of a model may be
too demanding or too costly for a modelling
exercise to be efficient. Sheldon35 described
modelling as a way of “reducing complexity to
simple elements in order to better understand the
way a system works or to predict its effects.”
However, if the model itself requires data collection
that is likely to consume significant resources, as
might for example the TAPSS model, the cost of
the preliminary modelling exercise might begin to
approach the costs of undertaking the assessment
itself, in which case the efficiency of the model and
its usefulness to health technology assessment
funding organisations come into question. Many of
the models lend themselves best to situations
where cost-effectiveness modelling of the
intervention has been previously undertaken.
The timing of the costs and benefits of
the technology
The timing of the costs and benefits relating to
the health technology assessment will affect its
overall cost effectiveness.36–38 It is unlikely that the
payback, and the costs of changes in
implementation, will occur immediately after the
trial.39 All the models considered above are able to
Health Technology Assessment 2003; Vol. 7: No. 20
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number of the applications on which the models
were tested did not do so. Related to this is the
potential lifespan of a technology. If a particular
technology or pharmaceutical considered for
assessment is expected to be superseded shortly by
a rival that is at an earlier stage of development,
then the shelf-life of the technology being
considered for assessment might be relatively
short and a substantial investment in the
assessment may not be efficient.40 The benefits of
the research over a given period need therefore to
be adjusted for varying shelf-life. The value of an
assessment may also be reduced or negated if
results of a similar or related assessment of the
same technology are pending.
Conclusions
Several useful models for prioritisation of
technology assessment have been set out in the
published literature. They share many common
features and cannot be seen as conceptually
independent. None, as formally presented, fully
met the criteria adopted. The most readily
operationalisable models, such as those of Eddy,
Drummond and co-workers, and Townsend and
Buxton, are based on decision analysis. The last of
these offers an easily applied model making
explicit use of weighted alternative options. Its
approach is demonstrated in summary in the
annex at the end of this chapter. The Drummond
model has the advantage that it uses expert
opinion as well as subgroup analysis. A synthesised
model is needed that draws on the best of these
existing models.
Annex to Chapter 2: 
an application of the
Townsend–Buxton model to a
proposal for the evaluation of
long-term use of hormone
replacement therapy
The Townsend–Buxton model was developed in
response to a request by the UK MRC and
Department of Health to evaluate the likely
payback to an extensive long running trial of HRT
that they were considering for funding. A
summary of the application of the model is given
here.
The model
The model is based on a sequential flow of
assessment, outcome, policy change, and health
benefits and costs (Figure 1).
Each outcome along a spectrum of possible
outcomes will have policy implications with
implications for different benefits, risks and costs.
For simplicity this spectrum of outcomes may be
narrowed. These may typically form a triage of
positive, negative or uncertain, and the scenario
analysis would form a sequence as shown in 
Figure 2.
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        A       O           P                 HE
Technology Vector of Policy change Resultant change in health benefits
assessment outcomes or economic outcome
(The trial) (Results) (Implementation) (Cost utility)
FIGURE 1 Assessment/policy sequence (A, assessment; O, outcome; P , policy change; HE, health benefits and costs)
        A       O           P                 HE
Assessment Vector of Policy vector Costs and health benefits of
exemplar for exemplar exemplar policy
 outcomes    outcomes
                   CEo            CEw
Cost-effectiveness of assessment Cost-effectiveness with
   for each exemplar outcome weighted probabilities
FIGURE 2 Scenario analysis sequence (A, assessment; O, outcome; P , policy change; HE, health benefits and costs; CEo, cost-
effectiveness of outcome; CEw, cost-effectiveness with weighted probabilities)The overall value of the trial would relate to the
stream of costs and benefits flowing from the
projected exemplar change of policy, the costs and
benefits of the counterfactual (status quo) and the
costs of the assessment itself, all discounted to a
baseline as given in equation (1):
[∑
t
∑
g
DCPotg – ∑
t
∑
g
DCNPotg + DCA]
CE0 = ————————————————— 
[∑
t
∑
g
BPotg – ∑
t
∑
g
BNPotg]
where CE0 is the cost-effectiveness for outcome o
and associated policy change p; DCPotg is the
discounted cost of policy change p for outcome o,
year t, group g; DCNPotg is the discounted cost for
the counter factual outcome o, year t, group g;
DCA is the discounted cost of the assessment
itself; BPotg is the benefit from policy change p,
outcome o, year t, group g; BNPotg is the benefit
given no policy change, outcome o, year t, 
group g.
The proposed trial scenario analysis
Research over many years had suggested that the
major long-term effect of HRT was a likely
reduction in risk of cardiovascular disease, stroke
and osteoporosis, principally coronary heart
disease.41 An RCT was proposed by the UK MRC
and was set to identify a 25% reduction in
ischaemic heart disease and stroke event rate
within 10 years for women treated with HRT for
10 years, compared with women on placebo for
the same time, with a power of 80% at a
significance level of 5%. Collaboration from
research centres in Europe and Australia was
proposed to raise the power of the trial. 
There was evidence that HRT also reduced the
risk of osteoporosis,42,43 but increased the risk of
breast cancer.44 The sample size for the proposed
trial was set on the cardiovascular events, but
other secondary end-points were included relating
to osteoporosis (hip fractures and vertebral
fractures) and breast cancer. The risk of hip
fracture occurs at an older age than cardiovascular
disease, and the trial would have needed longer
follow-up for this end-point and was set to detect
hip fracture after 20 years, following 10 years’
treatment; vertebral fractures were to be assessed
from a sample after 5 and 10 years, and the trial
was set to detect a halving of risk with 80% power
and 5% significance. European and Australian
collaboration was necessary to achieve power to
detect the effects of HRT on risk of breast 
cancer.
Evaluation: assumptions for exemplar
outcomes
For the ex ante assessment of the likely value of the
trial, three exemplar outcomes were considered:
(1) a ‘positive’ outcome showing clear long-term
benefits related to cardiovascular events and
fractures, outweighing any increase in risk of
breast cancer, and adding to the benefits of
reduced osteoporosis and short-term relief from
menopausal symptoms; (3) a ‘negative’ outcome
where there are negative long-term ‘benefits’ from
the therapy, although still short-term relief from
menopausal symptoms. The assumptions for the
negative outcome were that the cardiovascular
benefits were a quarter and fracture benefits a half
those for the positive outcome, whereas the
increase in risk of breast cancer would be twice
that under the ‘positive’ outcome. This was
considered a ‘worst case’ outcome on current
knowledge, i.e. a small cardiovascular benefit
suggested but counteracted by a higher breast
cancer risk. An alternative inconclusive outcome
(2) was the other scenario in which the
cardiovascular and fracture benefits were as in the
negative outcome, but with breast cancer risk as in
the positive outcome. This could present as an
‘inconclusive’, non-significant result, possibly due
to insufficient power.
Assumptions for policy implementation
scenarios and costs and benefits
Use of HRT following publication of the trial
outcome was predicted to 2027 (20 years) for each
of the three exemplar outcomes. These were based
on published data45,46 and modelling current
trends in the UK47 and USA, and on what seemed
‘reasonable’. Expert opinion other than from the
literature was not used. In each case costs and
benefits of HRT use were assessed net of the likely
use in the absence of the trial, assumed to be a
continuation of the trend up to an assumed
maximum, which was the current usage in
California.48 In the absence of the trial, benefits
would nevertheless vary according to the exemplar
outcomes, although these would not be known and
would not affect policy or cost of use.
Following a positive outcome (1), it was assumed
that the 50% of women aged 50–64 years currently
taking HRT short term (including the 10%
continuing to long-term therapy) would all
continue on to HRT long term. The net discounted
present value of this policy change over 20 years,
together with the present value of the trial costs,
was estimated at £598 million (Table 2). The
associated net benefit in terms of normal healthy
year equivalents gained was based on the
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effects of HRT on quality of life, and estimated as
1.7 million quality-adjusted life years (QALYs)
(0.35 million discounted), gained at a cost of £354
per QALY (£1709 discounted). For the
inconclusive outcome (2), no change in policy or
practice was assumed and so no net benefit or net
cost of the policy change. This indicates, for
example, the lack of return from a trial that is too
small to identify significant effects, so there would
be the cost of the trial for no information gain. If
there were a negative long-term outcome
(outcome 3), a policy change to ‘no long-term
usage’ was assumed. This negative implementation
would mean a reduction in net health service and
therapy costs which would be far greater than the
trial costs; there would also be an increase in
QALY benefit from avoidance of the long-term
disbenefit. This outcome, the health-service
‘dream’ outcome, would offer both a cost
reduction and a benefit increase.
Expected value of trial (weighted
analysis)
The outcome of the trial was obviously not known
a priori and so different likelihood or weightings of
each of the three considered outcomes were used.
These were that each outcome was equally likely
(weighting one-third each); that outcome 1 was
more likely (weighting 50%) and other outcomes
25%; and, less likely, that the negative outcome 3
was more likely (weighting 50%) and other
outcomes 25%.
The inconclusive result (outcome 2) would give the
costs of the trial for no benefits (infinite costs per
QALY).
Weighting the possible outcomes of the trial by
these assumed probabilities for each result allowed
estimation of the expected net costs and benefits
for the trial. Equal weighting resulted in an
estimate of £160 per QALY (£770 discounted);
higher weighting to the negative outcome resulted
in an estimate of £55 per QALY (£260
discounted). On current knowledge, however, the
most realistic assumption was represented by the
high weighting to the positive outcome, which
resulted in expected health gains in QALYs at a
cost of about £240 per QALY (£1150 discounted).
This best a priori estimate compared with an
estimated ex post benefit of £350 per QALY (£1700
discounted) for a positive outcome, a health
benefit and a cost saving for the negative outcome,
and cost for no benefit for the inconclusive
outcome.
Conclusion
The application of the model to the returns to the
trial suggested that it was likely to result in a
health gain in QALYs at an expected cost of £240
per QALY (£1150 discounted), with a range of
–£270 to +£350 (–£1270 to +£1700 discounted),
depending on whether the actual result was
negative or positive. Comparison with costs per
QALY from other studies showed that this
represented a lower expected cost than that of
Review of the literature
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Table 2 Implications of the exemplar outcomes and related policy change in the proposed HRT trial
Positive Inconclusive  Negative 
outcome 1 outcome 2 outcome 3
With trial
Net therapy/health-service cost discounted at 6% to 1994 (£ m) 1049.70 498.67 223.00
Trial cost (discounted to 1994) (£ m) 47.09 47.09 47.09
Benefits (QALYs million) 4.50 1.96 1.96
Without trial
Net therapy/health-service cost discounted at 6% to 1994 (£ m) 498.67 498.67 498.67
Benefits (QALYs million) 2.81 1.96 1.11
Net trial implications
Net costs (£ m) 598.12 47.09 –228.58
Net benefits (QALYs million, not discounted) 1.69 0 0.85
Net benefits (QALYs million, discounted) 0.35 0 0.18
Costs per QALY (not discounted) £354 Costs for no  Benefits +cost 
benefits saving 
Costs per QALY (discounted) £1709 Benefits +cost
savingsmany common health-service treatments, such as
that of renal transplant at £2000 per QALY
(£4500 discounted) or breast cancer screening at
£3000 per QALY (£5000 discounted).
The analysis depended on making assumptions
about the long-term effects of HRT which were
uncertain and which the trial was designed to
clarify. However, given the current knowledge, it
was judged that the analysis indicated that the
trial would be a ‘good buy’ in terms of common
health-service practice, whether the outcome was
to extend treatment or, if HRT proved to be non-
beneficial, to limit its use. In addition, as in any
assessment, there was likely to be additional
knowledge; in this case it would have given
profiles of health states and health-service use
through middle and into old age, for a sizeable
cohort of women taking HRT and those not
taking it. The project was funded.
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In the light of the analysis of existing models, this
section sets out a ‘synthesised’ methodology to
address the various problems previously identified,
while incorporating the strengths of existing
models identified in the literature review. It
essentially retains the separation of a first stage
that assesses whether and what type of research on
a technology is likely to be cost-effective and a
second stage that focuses on whether a particular
research proposal (for that topic) is likely to be
cost-effective, or which of a number of alternative
proposals is likely to be most cost-effective. The
general model is represented in Figure 3. Separate
quantitative analyses are applicable to the top and
lower halves of the model, assessing whether
uncertainty exists and if so in which area, as well
as to the stage of assessment of a specific health
technology assessment proposal. Before either
assessment, data are needed to decide the level of
uncertainty about the cost and/or effectiveness of
an intervention, and whether this uncertainty
reasonably prevents informed adoption or
rejection of the technology. If a reduction in
uncertainty would, given a particular outcome and
the necessary resources, lead to a beneficial
change in practice or policy, then a trial should be
considered. For specific research proposals, the
expected incremental cost-effectiveness ratio of the
research proposals could be determined using
equation (2). This ratio would be subject to
sensitivity analysis to allow for the uncertainty and
subjectivity around the inputs to the model. The
results of the application of the model would be
presented in a report to a research-funding
organisation, in which this expected incremental
cost-effectiveness ratio (EICER) would be weighed
with other payback considerations in the final
decision about whether the research project should
be funded or not.
The quantitative analyses in the model, as
summarised in equation (2), are designed to be
applicable at both the technology level (top of the
model) and the end of the algorithm, namely
whether a specific research proposal is likely to be
cost-effective. The analysis is based on three
alternative potential broad outcomes to an
assessment, and could be extended to include
multiple outcomes as appropriate to the context of
a specific technology. The three broad potential
outcomes include a favourable conclusion, an
unfavourable conclusion and an inconclusive
outcome. Each of these conclusions will have an
associated level of benefit (or disbenefit) and a
level of costs depending on the outcome and
effect on dissemination and implementation; there
will be an associated probability that the
assessment would result in that conclusion. The
EICER formula is:
EICER =
CT + p1(C1 – Cc) + p2(C2 – Cc) + p3(C3 – Cc) 
————————————————————— (2)
p1(B1 – Bc1) + p2(B2 – Bc2) + p3(B3 – Bc3) 
where CT = cost of the trial, n = trial outcome
identifier (1 = favourable to intervention, 2 =
unfavourable to intervention, 3 = inconclusive
result), Cn = cost associated with likely practice,
given trial outcome n, Cc = cost associated with
likely practice if trial did not occur, Bn = likely
benefits associated with likely practice given trial
outcome n, BCn = likely benefits associated 
with likely practice if trial did not occur, given 
the possible but unobserved outcome of the trial, 
pn = probability that trial will produce outcome n.
Figure 3 sets out the full PATHS model, from the
generation of ideas for assessment incorporating
horizon scanning through to the rejection or
funding of a specific research proposal.
The EICER could be used as a tool for health
technology assessment funding bodies at the
technology level or to assess potential returns from
proposed research. It would not be likely that
funds were available for all research with a
favourable EICER, but by comparing the expected
cost-effectiveness ratio of one or a series of
research technology areas or proposals within the
same area and the cost and effects of continuing
with the current provision, a funding body would
be in a position to allocate limited research funds
to provide the most efficient returns to research.
Each assessment would compare a range of
alternative implementation patterns following the
assessment’s conclusion, against the likely practice
in its absence, using a probabilistic framework. It
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Generate ideas for potential assessment
Initial assessment of technologies
Is there uncertainty regarding the technology’s costs or effectiveness?
Is the technology
cost-effective?
Call for studies on
effectiveness only
Is the study likely to be cost-effective?
Reissue call for proposals
Is uncertainty resolved by other existing
or proposed studies?
Call for trials and
economic evaluation
Might the extra
information lead to a 
change in practice?
Might the extra
information lead to a
change in practice?
Call for studies, economic
evaluation only, using existing
effectiveness data, or
modelling
Assess expected cost-effectiveness of proposal using data on the cost of the study, the
likely outcomes of the study, the likely implementation given these outcomes, the
probabilities associated with these outcomes occurring, possible alternatives to the
technology and the likely practice and benefits in the absence of the study
Might the extra
information lead to a
change in practice?
Costs: N
Effects: N
Y N
Y N
Y N
Costs: N
Effects: Y
Costs: Y
Effects: N
Costs: Y
Effects: Y
Change in
practice
Change in
practice
Change in
practice
Change in
practice
Recommend
adoption
Do not
recommend
adoption
Recommend that the study proceeds,
and provide information from the
preliminary evaluation to the research team
Do not proceed further with this proposal, 
but use information to guide decisions 
regarding other proposals
FIGURE 3 General outline of the PATHS modelwould measure the effectiveness of assessment in
terms of the primary outcome measure of the
research proposal itself using existing published
data, or expert opinion if necessary.
It would not require major data collection, would
be relatively straightforward to operationalise and
would be relatively transparent. Alternative values
for the net costs, benefits and probabilities for
each scenario could be incorporated. The extent
of the implementation can be adjusted allowing
the evaluation to reflect the likely impact on
practice within the health sector, as well as the
reduction in uncertainty.
Data for the model
Where empirical data are not available from the
literature or routine data sources for use within
the model, expert opinion would be used to
provide estimates. The choice of experts would
depend on the nature of the proposed trial under
analysis, in particular the level of intervention, but
would represent clinical, health-economic and
purchaser expertise to triangulate the estimates.
The clinician is important for making predictions
in the light of expert knowledge of both the
technicalities or intricacies of the subject and
current practice, and the likely impact of
alternative research findings on decision-making
and policy at the clinical and professional level.
The purchaser’s contribution would be from the
view of a more macro decision-maker who has the
experience of responding to new evidence and
allocating resources between different services.
The economist’s contribution would be technical
(understanding of cost utility analysis and decision
analysis) and would usually be made by a researcher
who has worked in the field under consideration
and so would be cognisant with the issues.
To operationalise the model the following
information would be needed:
  the likely development of policy or practice in
the absence of the assessment (i.e. current use
and likely trends): the counterfactual
  the likely implementation of the experimental
intervention following the reportings of the
assessment results, given alternative scenarios
for the results:
– the extent to which the technology or service
might be adopted
– how existing policy might affect the level of
implementation
– whether the technology or service would be
introduced for all potential candidates, or
whether it would be targeted at specific groups
  how other relevant services might be affected
following the adoption or change in practice of
the experimental intervention
  what measure would be most appropriate or in
the case of assessment at project level, whether
the outcomes used within the trial are
appropriate, whether they are likely to influence
future policy and/or practice and whether there
are alternative outcome measures that might be
more appropriate
  threshold levels of costs, effectiveness or cost-
effectiveness that might trigger adoption of the
experimental intervention
  probabilities of alternative outcomes of the
assessment (positive, negative or inconclusive).
Conclusions
This chapter and the previous one have
considered characteristics that a quantitative
model for the prioritisation of health technology
assessment projects needs to include. There are
inevitably trade-offs among the completeness of a
model, the resource implications of the modelling
exercise and the ease of operationalising the
model. A balance has to be struck among them.
The model presented here does not aim to replace
existing processes of research prioritisation, but
would be complementary to the process of peer
review and criteria-based approaches that consider
benefits that are not directly quantifiable. It aims
to fit within the existing processes and to be used
within an iterative framework.
Transparency is an essential characteristic of the
process as potential applicants need to know how
their proposal is to be assessed, and this decision-
analytical model is far more transparent than a
model using abstract methods to determine the
benefits of the research.
Use of a range of expert opinion would help to
obviate bias, and sensitivity analysis is relatively
straightforward in models based on decision-
analytical theory, as the costs, benefits and
probabilities of each arm can be easily adjusted.
Models in which the benefits are difficult to
disentangle may not be easily adjusted by
sensitivity analysis to account for uncertainty. An
attempt has been made to balance the issues of
rigour, transparency and resource requirements. 
Testing the model
It was considered important to test how the model
might work in practice. Ideally, this would have
been done prospectively on a cohort of proposals
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whether they would be funded. For those funded,
the ‘predictions’ from the ex ante evaluation would
be compared with the outcomes of the technology
assessments and the impact these had on policy
and practice. However, such real-time testing
would have been excessively lengthy and
impossible to undertake within the desired time
span of this study. As a realistic approximation,
therefore, the authors proposed to test and
evaluate the model on four case studies of already
funded randomised trials, identified in liaison with
the UK NHS R&D HTA programme and the
MRC. These case studies would continue to run
concurrently with the preliminary modelling
exercise then, later, would be completed before 
the release of results from the trials, so that the
evaluation results could be compared with the
model predictions using expert professional
opinion as to what impact the actual results were
likely to have on the future use of the technology.
A further intention was to provide a practical
guide to health technology assessment
organisations, particularly on the quantitative
assessment, that could be used as an adjunct to
current assessment procedures to prioritise
research or to appraise specific research proposals.
In the original proposal it was planned to carry
out eight case studies. In the commissioning
process the study was scaled down and four were
agreed. The MRC and the NHS HTA R&D
programme provided details of their ongoing
studies and four from only eight were identified
that fitted the criteria of being an RCT, including
an economic analysis and reporting within the
window of the second year of the study. The last
criterion was necessary so that the ex ante analysis
could be carried out before the trial reported, and
to conduct the ex post analysis during the study
period.
Two MRC- and two HTA-funded studies were
selected to include both surgery or other invasive
procedures and other non-invasive health services
research projects. In the event, only one of the
four cases reported on time. One reported late,
one had not been reported officially at the time of
the analysis, although the researchers have given
us confidential access to their results, and the
fourth case had been given an extension by the
MRC and had not been completed.
The following reports present assessments of these
case studies using the PATHS model. The
modelling exercises analyse the expected benefits
from undertaking each research project, and relate
these to the likely costs associated with
implementation of results and of undertaking the
trial itself.
For each case a summary of the research project is
first presented, followed by a report of the
interviews and predictions from the expert group,
the results from combining the routine data with
the information acquired from the expert groups
into the model, a discussion of the implications of
the analysis and the conclusions. This first section
of each case report contains the material that
could be presented to a potential funding body to
help to inform the funding decision. The final
section of each case report presents the actual
results and the costs and benefits of likely
implementation based on expert opinion and so
constitutes the tests of the model. The documents
sent to members of the expert group are given in
the appendices. The first set of documents sent
included project summary, protocols, some
relevant references and an outline of the questions
asked. The later documents sent after project
results were available included the article or report
in which the results were published (summary only
given here) and questions asked about likely
implementation.
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20Project summary
The trial of ‘The costs and benefits of postnatal
midwifery support’ aimed to evaluate the
effectiveness and cost-effectiveness of a postnatal
support service provided to mothers by
community midwifery support workers (CMSWs).
The CMSW was to provide the following services:
  establish a supportive relationship
  provide a personalised service with regular
contact to facilitate the recognition of signs of
problems
  reinforce midwifery advice and information
about breast-feeding and other issues
  carry out light housework
  encourage women to use the services of
healthcare professionals and other agencies
appropriately. 
The service would be in addition to the standard
current midwifery visits.
The trial planned to recruit 720 women over a 6
month period. Half of the mothers recruited were
to be randomly allocated to receive up to ten daily
weekday visits offered from the CMSW in addition
to standard care. The other mothers were to form
the control group and receive the current standard
midwifery postnatal care programme of ten
midwife visits up to the 28th day following
delivery and 24 hour telephone access to the
midwifery service until the 28th day. 
The trial aimed to evaluate whether or not the
intervention group receiving the CMSW service
had higher health status after 6 weeks relative to
the controls, as measured by the general health
perception dimension of the Short Form 36 
(SF-36). Secondary outcomes of postnatal
depression, breast-feeding rates, uptake of
benefits, level of economic activity, mother’s
feelings for her baby and confidence were also to
be measured. There was to be an economic
analysis to assess the cost-effectiveness of the
CMSW service by expressing the additional cost
incurred by the experimental intervention per unit
of health benefits produced, as measured by the
General Health Perception (GHP) dimension of
the SF-36.
Timings of the trial
The funding application was submitted in
September 1995 to start in April 1996. Follow-up
was completed in April 1999, with expected and
actual publication in July 2000. The initial expert
interviews were carried out during August 1998
and the final interviews in August 2000.
Data from experts
Four experts were asked to participate and were
interviewed by either JT or GH. They included
the Chief Executive of a Community Trust for the
perspective of funding the service change within
the perspective of purchasing of community
services generally, a Director of Family Health
Services for the perspective of detailed
professional knowledge of midwifery services and
allocating a midwifery budget, a Professor of
Midwifery for a wide academic and professional
knowledge of both midwifery services and research
methodology and outcomes, and a health
economist with experience in undertaking
economic evaluations of postnatal services for the
perspective of cost-effectiveness.
Four people were approached who fitted these
categories and all agreed to take part in the study
as expert advisors. A pack was sent to each
(Appendix 2) including a synopsis of the proposal,
copies of four key papers available at the funding
decision date49–52 and the questions on which their
opinion was sought.
They were asked how, at the time of funding in
1994, they would have expected the provision of
postnatal care to have developed had the trial not
been funded, the likely growth of ‘selective
visiting’ or the likely adherence to the national
rules of ten daily postnatal midwife visits. They all
thought that selective visiting would have been
likely to continue to grow in the absence of the
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midwifery supporttrial, with local midwifery services gradually,
officially or unofficially, dropping adherence to the
national rules. 
They said that if the trial found in favour of the
CMSW service then, on average, approximately
25% of midwifery services might well change their
practice to incorporate a CMSW service where
appropriate. They all thought that in the
counterfactual situation, without the trial, such a
service might be used in any case, with possibly up
to 5% of units introducing such a service within
the near future. To what extent and how quickly a
service might be introduced after the successful
results of a trial were published, would depend
partly on the means of dissemination. The ability
to implement would depend on the recruitment
and retention of staff needed for a comprehensive
service. It was suggested by two of the experts
that, were the conclusion to be in favour of the
CMSW service, midwifery services might
accommodate the costs by targeting the service to
a specific geographical area, or a set of women
identified as being high risk, and that the limited
service might be run for, say, 6–12 months as a
pilot service to assess its value and acceptance.
Were the results to be negative, that is, the women
receiving the CMSW service had a lower health
status than those receiving the standard care, there
was agreement that adoption of the service would
not occur, although all experts said that a few
midwifery services might still adopt or retain a
limited service despite the conflicting evidence,
because it was a new idea, because they were not
concerned by cost implications or because they
saw advantages in terms of equity and so might
use the service for high-risk women only. Were the
trial results inconclusive, it was suggested that
further research or pilot projects might be
undertaken. In this case, it would be likely that the
services might continue according to the existing
trend without the trial, with a very few services
adopting a CMSW service as part of further
research or pilot projects, as described above.
Outcome measures
The experts considered the outcome measures to
be relevant, although there was considerable
scepticism about how meaningful the GHP
dimension of the SF-36 would be to policy makers.
This was the main end-point and so was crucial.
The secondary end-points of postnatal depression
and breast-feeding rates were identified as more
important and likely to be more appropriate in
influencing policy. Several of the experts would
like to have seen other outcomes measured,
including the baby’s behaviour, family relations,
the interaction between mother and infant, and
sleeping difficulties. In summary, it was felt that
the study could have included more outcomes
concerning the baby, the interaction between
mother and baby and other family dynamics, and
that the main end-point was difficult to interpret.
Cost threshold
The experts were asked whether they thought
there would be threshold levels of costs or cost-
effectiveness above which the implementation of
the more effective protocol would be prevented.
All responded that no improvement in the SF-36
would be likely to affect policy unless it were
shown to reduce costs, owing to the pressure on
existing maternity service resources, the shift of
power towards primary care groups and the likely
reluctance of general practitioners (GPs) to divert
resources from other areas to such a service.
However, if the intervention resulted in a
significant improvement in breast-feeding rates
and/or postnatal depression, this was seen as likely
to encourage adoption of the service at an
incremental cost of up to £150 per woman. It was
thought that improved scores in the GHP of the
SF-36 were likely to be highly correlated with
improvements in factors such as breast-feeding
rates and postnatal depression. An improvement
of five points in the SF-36 was not seen as
significant for policy, but a 25-point improvement
was, and was seen as likely to trigger adoption.
Between these two levels of improvement, the
interaction of the other variables was thought to
be important. In addition, it was thought that the
hidden, indirect costs of reorganisation, when
added to the direct costs of the CMSW service,
might make a small improvement less attractive
and unlikely to affect policy. The distribution of
any benefits was considered important, with a
small but widespread increase seen as preferable
to a large but concentrated improvement, if the
decision were to provide a blanket service.
The experts all emphasised that there was little
slack in midwifery services and that any extra costs
would need to be met by cuts from other areas
such as antenatal screening or counselling services.
An alternative view from one expert was that
£50,000 per service could be found if wished from
vacancies not filled. It was argued that NHS Trusts
would be unlikely to make any significant
reduction in acute services for fear of litigation.
These opinions were used in the model to assess
the EICER of this trial, outlined in the next
section.
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22Model parameters, results and
discussion
The costs and benefits of the service for a period
of 5 years following publication of the trial results
were estimated and discounted to present value at
the time of trial funding. Five years was considered
an appropriate time horizon owing to the rapid
change in delivery of midwifery services, which
might make results irrelevant after this time.
The service was costed on a per-mother basis. The
trial proposal gave the starting salary of a CMSW
as £10,375 and the training costs as £70 per
CMSW. Based on the protocol information that a
CMSW could see three mothers a day and each
mother would receive ten visits in the postpartum
period, a CMSW would on average see some 66
mothers per annum. Dividing the annual direct
cost of providing one CMSW by the number of
mothers seen by the CMSW, we arrive at an
approximate cost of £157 per mother, which is
rounded up to £160 and will be subject to
sensitivity analysis. This figure, related to the
proportion of mothers expected to receive the
CMSW service following the publication of the
trial’s results, determines the main cost associated
with implementation. The proposal defined
effectiveness of the trial in terms of the primary
end-point of GHP profile of the SF-36. The total
population health improvement (or reduction)
from the service was therefore identified by
multiplying the number of mothers likely to
receive the service by the average expected health
gains (or losses) in terms of points increase on the
GHP.
The expected changes in cost and effectiveness
were used to assess the EICER of the trial,
expressed as the expected cost per point
improvement on the GHP. Scenarios, representing
positive, negative and inconclusive outcomes of
the trial, are modelled using varying degrees of
implementation based on expert judgement and
the likely average health benefit.
The birth rate was assumed to be stable over the
period concerned (5 years) and it was assumed
that the staff dropout rate does not require the
training of additional CMSWs.
As reported above, there was agreement that even
in the absence of the trial, a small number of
midwifery services would introduce a limited
midwifery support service similar to the one under
evaluation in this study. The model incorporates
this prediction in calculating the net costs and net
benefits of the trial: it was estimated that this base
level was approximately 5% of the total number of
maternities. Any change would be phased in over
3 years.
Table 3 sets out three possible alternative trial
outcomes and subsequent implementation
scenarios identified from the interviews. The costs
of the trial and the costs and the benefits of the
implementation following each trial outcome are
calculated for these three scenarios. In each case
we have identified the costs and benefits that
would have occurred without the trial, assuming
the baseline service to 5% mothers indicated by
the experts, in order to calculate the net
implications of the trial. Table 4 presents the costs
and benefits with and without the trial for each
scenario, the net costs and net benefits of the trial,
and the incremental cost per point improvement
in the GHP. Costs are discounted at 6% and
benefits at 2% to 1994, when the funding decision
was made. 
A positive outcome of the trial, scenario A, results
in net discounted costs of £37 million over 5 years.
These net costs are offset by an increase in benefits
over the counterfactual to the trial of nine million
points improvement in the GHP of the SF-36 over
the whole population. This implies a cost per
point of £4.20. Scenario B is the inconclusive
result. It assumes that there are no health gains
and there is a limited degree of implementation.
As such, the net costs of the trial would be £0.22
million, for no net health gain. Scenario C, the
negative outcome, would result in a net saving of
£9.2 million owing to reduction in the service, and
a small net benefit of about a third of a million 
SF-36 points improvement, owing to the service
being withdrawn from mothers who would have
received the service if the trial had not gone
ahead. There is no trade-off between cost and
benefit of the trial under this scenario; that is,
there would be both a cost reduction and a health
gain: the dream scenario. Only one of these
scenarios will transpire, and so the estimated net
outcomes need to be combined in a probabilistic
framework to bring together the overall expected
value of the trial (in subsequent cases, the experts
were asked to estimate the probabilities of each
outcome). By assigning probabilities to each of the
scenarios, an expected cost per point
improvement could be calculated. Three different
weightings were used to cover a wide range of
possibilities. Combination 1 is an optimistic
combination, with a 50% likelihood of scenario A,
and 25% of scenarios B and C; combination 2 is a
pessimistic combination, with a 50% likelihood of
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TABLE 3 Scenario assumptions
Trial outcome Implementation scenario
A (positive)
Trial shows that CMSW service is effective and cost-effective:
• on average, a 25-point improvement in the GHP profile of
the SF-36
A
Following the trial, implementation extends to the majority
of services, but to a limited proportion of mothers:
• service provided to 25% of mothers in the postnatal
period phased in over 3 years
• no increase in the number of GP visits
B (inconclusive)
Trial finds marginal improvement in health status due to
CMSW service:
• on average, no improvement in the GHP profile of the 
SF-36
B
Following the trial, the majority of midwifery services do
not adopt the service, although several continue to provide
the service, and some innovative departments develop a
limited CMSW service:
• service provided to 5% of mothers in postnatal period
• on average, an increase of one GP visit in 10% of the
women receiving the CMSW service
C (negative)
Trial finds that mothers without the CMSW service have
higher health status:
• on average, a five-point reduction in the GHP profile of the
SF-36 for those with the CMSW service
C
Following the trial, owing to either poor dissemination or
the inability to extrapolate the trial results to local settings, a
minority of departments continue to provide a CMSW
service:
• service provided to 2.5% of mothers in postnatal period
• on average, an increase of two GP visits in 10% of the
women receiving the CMSW service
TABLE 4 Cost and benefit calculations for the UK
Scenario A Scenario B Scenario C
Trial result: Positive Inconclusive Negative
Without trial
Net cost (£ m) 18.9 18.9 18.9
Net benefits (million points of GHP of SF-36) 3.20 0 –0.64
Trial
Trial cost (£ m) 0.223 0.223 0.223
Following trial (5 years)
Cost (£ m) 55.6 18.9 9.5
Benefits (million points of GHP of SF-36) 12.04 0 –0.32
Net trial implications
Net costs (£ m) 36.9 0.22 –9.2
Net benefits (million points of GHP of SF-36) 8.8 0 0.32
Cost/point of GHP of SF-36, as a result of trial and  £4.20 NA (savings + benefit)
subsequent implementation
NA: not applicable.
TABLE 5 Expected costs and benefits
Combination 1 Combination 2 Combination 3
Expected costs (£ m) £16.205 £4.68 £9.307
Expected benefits (million points) 4.48 2.36 3.04
Expected cost/point £3.62 £1.98 £3.06scenario C, and 25% of scenarios A and B;
combination 3 is the neutral combination, with
33% likelihood being assigned to all three
scenarios. The final weighted results are
summarised in Table 5.
Owing to the high costs associated with scenario A,
the expected cost per point is not highly sensitive
to the probabilities, and improvement under all
three combinations is within the range of £2.00 to
£3.60 per point improvement (calculations for
Table 5 use cost and benefits figures from Table 4
rounded up to the nearest thousand).
Conclusions
In evaluating the likely returns to the proposed
research, the authors have tried to assess the likely
payback in terms of discounted future costs and
benefits flowing from the implementation of the
results, and have also addressed issues around the
research design, dissemination and likely
implementation of the research findings.
The main conclusion from this study is that the
expected cost per one-point improvement in the
GHP scale of the SF-36 is between £2.00 and
£3.50. When this is translated into the gain
suggested by the expert panel as one which would
bring about change, that is a 25-point
improvement, it implies a maximum net cost of
introducing the technology of approximately £50
to £90 per mother. This cost would be well below
the experts’ threshold of £150 per mother for
implementation were there a significant
improvement in breast-feeding rates or
depression, and which they thought would be
highly correlated with a 25-point improvement in
the GHP.
The proposal is therefore assessed as ‘good value
for money’ on the basis of the estimated stream of
benefits and costs compared with the threshold
level for SF-36 points and costs given by the
experts. An important issue arises here in the
translation from ‘statistically significant’ to
‘clinically important’. The experts were not clear
that the reporting of an improvement of 25 points
in an SF-36 scale would bring about a change in
practice, owing to the lack of understanding of its
meaning by decision-makers. The expert group
was more interested in the secondary outcome
measures, especially breast-feeding rates and
postnatal depression, as being more likely to
influence commissioners and providers of family
and maternity services, although they thought that
the primary end-point was likely to be correlated
with these.
According to the experts, in the face of
‘inconclusive’ evidence, the net changes in policy
compared with what would have happened if the
trial were not funded would be minimal and
therefore the net costs and benefits, although very
low, would bring no returns to the cost of the trial.
In contrast, scenario C, were it to be the outcome,
would be an ideal scenario and the best value for
money, with a net saving over 5 years of £9.2
million, and a net increase in health status of 0.32
million points in the GHP of the SF-36. Neither of
the two conclusive outcomes is therefore
unattractive. 
The overall conclusion would be a
recommendation to fund the trial, but with two
design changes. If the results are to convince
providers of maternity services, it would be
preferable that the trial was set to detect a
significant change in breast-feeding rates or in
postnatal depression (the trial includes but is not
designed to detect any such differences), with
emphasis on these rather than the observed
differences in the GHP profile of the SF-36. The
experts would also like to see other child-related
outcomes, as set out above. The other issue that
was emphasised would be to consider subgroups of
women at relatively high risk, as a service directed
at these women might be more cost-effective and
more likely to be implemented. 
This report was written following interviews with
the expert advisors in July 1998, 2 years before
the publication of the results of the trial, which
follow.
Actual results of the trial
The results of the trial were published in March
2000 as a Health Technology Assessment.53
The main results were as follows.
  In total, 623 women were randomised, they
were well matched between intervention and
control groups and there was a good response
to follow-up.
  At 6 weeks there was no evidence of a
significant difference between the groups for
the primary outcome (GHP domain of the 
SF-36).
  There was a non-significant trend for the
control group to have better Duke Functional
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Post Natal Depression (EPDS) score at 6 weeks.
  There was no significant difference in breast-
feeding at 6 weeks.
  At 6 months both groups had similar health
status.
  Satisfaction with the new service was the highest
of all postnatal services received.
  There was no difference between the groups in
the use of other services (GP contacts, hospital
services, prescriptions or medicines for mother
or baby).
  The total mean NHS costs to 6 month follow-up
were £180 higher for the intervention group
(confidence interval £79.60 to £272.40). This
included setting up and running the service. 
The researchers concluded that although women
valued the service there was no evidence of any
health benefit at 6 weeks or at 6 months and no
difference in health-service use, but an extra cost
of £180 per woman, and that additional studies
are needed to identify support-related outcomes of
importance to postnatal women and to compare
the effectiveness of different models of antenatal
and postnatal support.
Testing of the model
Following the publication of the report, a copy was
sent to each of the experts, together with a second
set of questions (Appendix 3).
Related to the three possible scenarios considered,
the outcome falls between inconclusive and
negative and would fail the experts’ cost threshold
for implementation.
Ex post interviews with experts: their
predictions of effects of the trial
results on subsequent policy
Implementation
All of the experts said that they would not
recommend nor expect take-up of the CMSW
service, and that where in use they would
recommend and expect reduction of the service.
However, they all also said that they thought the
service might continue for certain at-risk groups.
Each expert suggested a different at-risk group:
one suggested ethnic minority groups, particularly
Asian women, who tend to have low breast-feeding
rates, and another suggested low-income families.
(Some of these may have been specifically
excluded from the trial in the exclusion criteria of
not speaking or understanding English, having a
baby requiring special care in a baby unit, or being
aged 16 or below.) If introduced for an at-risk
group, they thought this would happen over 3
years. If reduced, this would take 1 year and would
require careful handling and presentation of the
evidence. It was anticipated that there would still
be a minimal service operated across the country,
possibly to some 3% of mothers (from an existing
base level of possibly 5%). One of the experts
advised that there should be continued service for
at-risk groups, with audit and further research
including willingness to pay.
Outcomes
The experts were asked which of the outcome
measures influenced their predictions and to put
the measures in order of importance to them.
Three put breast-feeding and depression first and
one said that these were the only outcomes of
relevance. One put patient satisfaction first. Three
added SF-36, SF-36 GHP (the major end-point
used for power calculation) as third or fourth;
client satisfaction (the outcome that favoured the
intervention) was dismissed by one, put in first
place by another and in fifth by the other two, so
there was disagreement about its role.
Dissemination
To achieve dissemination of the results it was
suggested that they should be published in a
midwifery journal and sent to heads of midwifery
departments (expert A); then they should be
disseminated to midwifery liaison committees,
press releases, Community Health Councils,
midwives and support workers and there should
be feedback to The Netherlands, where the service
is in general use (expert B); and funds should be
sought for a national meeting on the current state
of postnatal support possibly linked to Sure Start
and other interventions (expert C). The fourth
expert also recommend peer-reviewed publications
and conferences (expert D).
Overall comments on the trial
  Expert A thought that, in general, postnatal
visits should be reduced and early discharge
extended, and the savings spent on teaching
parenting skills and giving vouchers for
takeaways where postnatal domestic support was
needed.
  Expert B thought that the study was very useful
as it provided proper evidence-based results,
and that further research should look at
substituting midwives and/or health visitors for
CMSWs.
  Expert C thought that it was a good study,
carefully conducted with appropriate methods,
and was being scrutinised by researchers
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social support.
  Expert D thought it a useful, well-conducted
study, but limited by not using sensitive enough
tools, long enough follow-up or at-risk groups.
Modelling ex post predicted
outcomes
The ex post expert agreement was for a reduction
in the service (which was currently thought to be
running at a level of implementation of about 5%)
to a level of about 3%, and that this reduction
would take about 1 year to implement.
This would bring about a cost saving of the service
to 2% of all mothers, saving £180 per mother. As a
5 year time horizon is used for this case, the
saving would be for years 2–5 discounted at 6%
back to the funding of the trial (1994), which
represents a saving of £5.86 million. The cost of
the trial was £0.223 million, leaving a saving of
about £5.6 million. There could be some loss of
mothers’ satisfaction from the service, but also
some reduction in depression, as lower rates of
depression were noted in the control group. The
savings would be higher if a longer time horizon
were considered.
The ex post results confirm the value of the study
as assessed in the ex ante evaluation; the negative
outcome, resulting in a reduction of the service,
gains the maximum value from the study. The
results are dependent on the assessment of the
likely reduction in use of the service and on the
baseline estimates given by the experts. It is
interesting, therefore, to consider the sensitivity
level for the break-even point of service reduction.
The 5 year savings would match the cost of the
trial if the reduction in service were considerably
lower than 2%, i.e. only 0.08%. The results are
therefore robust and the model successfully
predicted the trial to be cost-effective.
This is an area in which there has been little
research. It is therefore likely to have the added
benefit of training the researchers employed on
the trial and the participating services. It may also
be considered useful in suggesting future research,
particularly in developing or identifying
appropriate outcome measures in an area of
considerable public health concern and sensitivity.
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The NHS R&D HTA-funded trial ‘A randomised
controlled trial of prehospital intravenous fluid
replacement therapy in serious trauma’63 is the
second case study for testing out the model. The
aim of the modelling exercise is again to analyse
ex ante (as at before funding) the expected returns
from undertaking the research project, and to
relate these expected returns to the likely returns
estimated ex post (after publication of results),
associated with subsequent implementation and
undertaking of the trial itself. 
Project summary
The project aimed to evaluate the use of
cannulation and fluid infusion by ambulance
personnel in severely injured adults, in response to
the debate among professionals and within the
published literature about the uncertainty
surrounding the benefits of intravenous fluid
replacement on-scene. Evidence surrounding the
effectiveness of on-site infusion was inconclusive.
Some argued that on-site infusion stabilised
patients haemodynamically, resulting in a better
patient outcome. Others argued that infusion,
rather than stabilising the patient, might result in
elevation of the blood pressure, increased blood
loss and delay associated with establishing an
intravenous line. This might lead to an increase in
the time taken to transport the patient to the
hospital, resulting in a worse outcome. These two
opposing views were tested, comparing two
protocols in the trial as follows.
  Scoop and run: following basic life support, the
patient was to be transported immediately to
hospital if the time from arrival on-scene to
arrival at the hospital was estimated to be over
40 minutes.
  Field stabilisation: following basic life support,
an intravenous line was to be established and the
patient infused with a crystalloid/colloid mixture,
unless the estimated time from arrival on-scene
to arrival at the hospital was less than 15 minutes.
The unit of randomisation was the paramedic: 
420 paramedics in two ambulance services were
randomised to follow one or other of the two
protocols under strictly defined circumstances.
Halfway through the study the randomisation was
crossed over to avoid bias.
The trial aimed to determine which protocol was
the more effective primarily in reducing mortality
but also morbidity over a 6 month period, and
which was the more cost-effective from an NHS
perspective. To investigate this, the study followed
up patients over a 6 month period and recorded
all contacts with health services. General health
status was measured by the SF-36. The trial
economic analysis was to be expressed by the
marginal cost of the field stabilisation protocol
service alongside any marginal benefits in terms of
reduced mortality and/or disability.
Timings of the trial
The funding application was submitted in July
1994 to start in September 1995. Follow-up was
completed in September 1998; the report was
made available to the authors in June 2000 and
published in November 2000. The first set of
interviews was carried out in February 1999 and
the final interviews in July 2000.
Data from experts
Four experts were approached to participate and
were interviewed by either JT or GH. The panel
included a Consultant in Emergency Medicine for
professional knowledge of the procedures and
outcomes, a Medical Director of an Ambulance
Service for professional knowledge of the service,
paramedics and policy, a Chief Executive of an
NHS Trust for the broad expenditure priorities,
and a health economist with experience in
undertaking economic evaluations of pre-hospital
services for the perspective on cost-effectiveness.
All those approached agreed to take part and a
pack was sent to each (Appendix 4), including a
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Chapter 5
Case study 2: an RCT of infusion protocols in 
adult pre-hospital caresynopsis of the proposal, copies of eight key
papers54–61 (all short) available at the time of the
funding decision data, and the questions on which
their opinions were sought. They were asked how,
at the time of the trial funding in 1995, they
would have expected the provision of pre-hospital
care to have developed had the trial not been
funded, in particular whether or not, or what
proportion of patients would be cannulated before
transfer to hospital.
They were in agreement that there would have
been a gradual shift away from field stabilisation,
which was already losing favour, towards a policy
of scoop and run, unless the transfer time implied
that stabilisation was necessary. Each said that if
the trial found in favour of the scoop and run
protocol, this shift away from field stabilisation
would be accelerated. If, however, the trial found
in favour of field stabilisation (i.e. mortality was
significantly lower in those patients cannulated on-
scene, and the protocol was cost-effective), then
there was likely to be a switch in policy where
appropriate. However, the rate at which
ambulance services would be likely to switch to
employ this protocol would be slower than if the
scoop and run protocol was favoured, as it would
be counter to the current trend. Were the trial
results inconclusive, it was felt that the current
trend would continue, but perhaps at a slower rate
than if the trial found in favour of scoop and run.
These projections were incorporated into a 10
year model for each scenario shown in detail in
the next section. There is little definitive research
in this area and it was felt that the findings were
likely to hold for a relatively long period, although
new developments might overtake after this time.
The experts were asked which of all the outcome
measures used within the study was the most likely
to influence practice among ambulance services.
The accident and emergency (A&E) consultant
said that the quality of life measures would be
most important, as mortality would be most
unlikely to be affected by the protocol difference.
The three other experts agreed on mortality, the
primary outcome measure of the trial, as the most
important outcome. In accordance with the trial
protocol, mortality was used to calculate the
EICER in this exercise, while recognising that
morbidity and disability are important outcomes
not considered explicitly within the quantitative
modelling.
The experts were asked whether they thought
there were threshold levels of costs or cost-
effectiveness above which the implementation of
whichever protocol was found to be more effective,
would nevertheless not be used. They
unanimously agreed that cost differences between
the protocols to the NHS were likely to be small
and not likely to be barriers to implementation.
Implementing changes that went against intuition
or the existing trend might be difficult, however,
but not for cost reasons. They considered that
organisational or professional barriers to the
adoption of the more effective protocol were more
likely than cost barriers.
They were also asked, given their knowledge of
current evidence, what they thought the results of
the trial were likely to be. The general agreement
was for a result in favour of the scoop and run
protocol as the most likely outcome, with a
probability ranging from 0.4 to 0.5. Probabilities
for an inconclusive outcome and for favouring
field stabilisation were each put between 0.25 and
0.3. The A&E consultant said ominously that
uncertainty is always the real outcome of such
studies.
These opinions were used in the model to assess
its likely incremental cost-effectiveness ratio.
Model parameters, results and
discussion
The costs and benefits flowing from the different
scenarios were calculated for a period of 10 years
on a per life saved basis, according to the likely
change in practice. Differences in patient
management as a result of different patient
outcomes between the two protocols or the
protocol itself would occur on-site, during
transport to hospital, in the A&E department, in
inpatient departments, and in the primary and
community care setting. There could be further
cost or quality of life differences if patients
recovered more quickly after one protocol, or
there were more seriously disabled survivors. The
unit cost of each service was identified using the
‘Unit costs of health and social care’ 1998, as
determined by the Personal Social Services
Research Unit.62 Likely levels of demand for 
these services were suggested by the expert
advisors.
Three possible alternative trial outcome scenarios
were explored: favouring scoop and run, an
inconclusive outcome and favouring field
stabilisation. Mortality associated with each
protocol, and the net effect on practice following
the trial’s conclusion were assumed to vary for
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the expert opinion as set out in Table 7. 
It was assumed that the number of trauma
patients per annum would not change significantly
over the period concerned. The calculations are
based on the mean number of trauma patients
treated by a non-metropolitan ambulance service
each year.
As reported in the previous section, there was
agreement that a gradual policy shift towards
scoop and run was currently occurring, and would
have been likely to continue in the absence of the
trial. Table 6 shows the assumed pattern of practice
over the 10 years in the absence of the trial, based
on the expert predictions.
Table 7 presents the alternative trial scenario
outcomes considered and the subsequent likely
implementation patterns, based on the expert
opinion. These are described in terms of the
significant difference in mortality observed in the
trial between the two protocols. To allow for
potential variations, calculations were made for
each scenario using alternative assumptions. One
assumed a relatively high level of health services
utilisation. Variations in cost-effectiveness may
occur owing to lower levels of mortality resulting
in post-trauma survival of people with high levels
of disability or morbidity, requiring higher levels
of resources (and therefore higher levels of
expenditure) in the 6 months following the
trauma. Table 8 presents the assumptions of the
unit costs, based on data from the protocol and
from ‘Unit costs of health and social care’
published by the Personal Social Services Research
Unit.62 It also sets out alternative levels of health
services utilisation.
For each scenario, the costs of the trial and the
costs and the benefits of the implementation
following each trial outcome were calculated using
the assumptions in Table 8 based on published
data and expert opinion. For each implementation
scenario the costs and benefits that would have
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TABLE 6 Proportion of relevant trauma patients treated by scoop and run and field stabilisation protocols in the absence of the trial
Year
12 3456 789 1 0
Scoop and run (%) 50 60 70 70 70 70 70 70 70 70
Field stabilisation (%) 50 40 30 30 30 30 30 30 30 30
TABLE 7 Scenario assumptions
Trial outcome Implementation scenario
A
Trial reports that scoop and run is more effective:
• 10% mortality in patients receiving scoop and run against
20% mortality associated with field stabilisation, resulting
in a favourable incremental cost per life saved for scoop
and run
A
Following the trial, the shift towards scoop and run is
accelerated:
• 90% of all relevant patients are treated using the scoop
and run protocol within 4 years
B
Trial does not provide conclusive evidence regarding the
effectiveness of field stabilisation compared with scoop and
run:
• minor improvement in mortality associated with scoop and
run (20% vs 20%)
B
Following the trial, the existing trend, i.e. the gradual shift
towards using scoop and run, occurs, but at a much slower
rate:
• 70% of relevant patients receive scoop and run by the
sixth year after the trial
C
Trial reports that field stabilisation is the more effective
protocol:
• 10% mortality associated with field stabilisation vs 20%
mortality associated with scoop and run
C
Following the trial, there is a gradual reversal of the existing
trend:
• 90% of patients are stabilised on-scene by the fifth yearCase study 2: an RCT of infusion protocols in adult pre-hospital care
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TABLE 8 Unit costs and utilisation rates
Low utilisation High utilisation
Ambulance cost (£/minute) 4.46 4.46
Journey time (scoop and run) (minutes) 40 40
Journey time (field stabilisation) (minutes) 60 60
A&E cost (£) 150 150
ITU cost (£/day) 300 300
ITU length of stay (days) 1 2
Ward cost (£/days) 200 200
Ward length of stay (days) 6 8
Readmission cost (£/day) 200 200
Readmission length of stay (days) 4 7
Outpatient cost (£/visit) 80 80
No. of outpatient visits 3 6
GP cost (£/consultation) 15 15
No. of GP visits 2 3
ITU: intensive therapy unit.
TABLE 9 Cost and benefit calculations: high health services utilisation (UK)
Scenario A Scenario B Scenario C
Trial result: In favour of scoop and run Inconclusive In favour of stabilisation
Without trial
10 year treatment cost (£ m) 786 729 758.1 
Benefits (discounted lives saved) 196,450 181,270 188,750
Trial
Trial cost (£ m) 0.2603 0.2603 0.2603
Following trial (10 years)
10 year treatment cost (£ m) 797.1 730 803.9
Benefits (discounted lives saved) 200,300 181,270 199,400
Net trial implications
Net costs (£ m) 11.4 0.87 46.1
Net benefits (thousand discounted lives saved) 3850 0 10,650
Cost per life saved £2960 NA £4330
NA: not applicable.
TABLE 10 Cost and benefit calculations: low health services utilisation
Scenario A Scenario B Scenario C
Without trial
10 year treatment cost (£ m) 515.3 479.1 497.6
Benefits (discounted lives saved) 196,450 181,270 188,750
Trial
Trial cost (£ m) 0.2603 0.2603 0.2603
Following trial (10 years)
10 year treatment cost (£ m) 521.3 479.5 529.6
Benefits (discounted lives saved) 200,300 181,270 199,400
Net trial implications
Net costs (£ m) 6.3 0.26 32.3
Net benefits 3850 0 10,650
Cost per life saved £1640 NA £3030
NA: not applicable.occurred without the trial have also been
estimated and subtracted. This provides the net
implications of the trial, presented in Tables 9 and
10, together with the net cost per life saved for
each scenario, under the high and low utilisation
assumptions.
Tables 9 and 10 present the results of the modelling
exercise. The high utilisation group would relate to
those with higher disability and morbidity, as they
would need more contact with health services in
the aftermath of a traumatic accident. Were the
results in favour of scoop and run (scenario A), the
net costs over 10 years are estimated to be 
£11.4 million for the high utilisation setting, and
£6.3 million for the low utilisation setting. The
reduction in mortality associated with the
associated policy change would lead to
approximately 4000 lives saved over 10 years, at a
cost per life saved of £3000 or £1600 for high or
low use of services, respectively. Scenario B, the
inconclusive outcome, would result in a small
increase in costs owing to the cost of the trial and
slower trend to field stabilisation after the trial
than would have occurred had the trial not been
funded, but with no difference in mortality.
Scenario C would result in higher net cost levels.
This is due to higher costs associated with longer
ambulance journeys (see Table 8). In addition, the
potential reduction in mortality does not impact as
quickly, owing to the slower diffusion rate against
the previous trend. The net costs of this scenario
after 10 years would be £46.1 million and £32.3
million for the two service utilisation settings. The
reduction in mortality would result in 10,650 lives
being saved over the 10 years, giving a cost per life
saved of £4330 for the higher and £3000 for the
lower service use. To obtain the net returns to the
trial, the estimates need to be combined
probabilistically to determine the EICER. The
probabilities assigned were as shown in Table 11.
By weighting the net costs and net benefits for
each outcome using the expert or equal weight
probabilities in Table 12, the EICERs of the trial
and the subsequent implementation have been
calculated for each combination. These are given
in Table 13.
Turner et al63 showed that the distribution of ages
of patients attended by an ambulance is relatively
even. Taking the mean age of a patient as 45 years
and the normal life expectancy as 75 years, and
assuming that the saved patient survives and lives
a healthy normal life, the expected incremental
cost per life year, of the 30 years saved, under the
most pessimistic assumptions would be
approximately £130 per life year saved (and
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TABLE 11 Probabilities of outcome combinations
Probabilities
Trial outcome Expert mean Equal weights
Favours scoop and run 0.450 0.33
Inconclusive 0.275 0.33
Favours field stabilisation 0.275 0.33
TABLE 12 Expected incremental costs and benefits from the trial: high utilisation
Experts’ weighting Equal weighting
Expected costs (£ m) 18.031 19.246
Expected benefits (lives saved)  4660 4830
Expected cost/life saved 3870 3980
TABLE 13 Expected incremental costs and benefits from the trial: low utilisation
Experts’ weighting Equal weighting
Expected costs (£ m) 11.880 12.938
Expected benefits (lives saved) 4660 4830
Expected cost/life saved 2550 2680approximately £85 for the lower estimate). The
lower estimate assumes that the survivor lives at
full health. 
Conclusions
These estimates could represent advice to a
research funding body about the likely returns to
the proposed research. The conclusions relate to
the likely payback in terms of costs and benefits
and EICERS, and include useful insights about the
research design and necessary dissemination,
which would be of interest to a research team as
well as to potential funders.
Given the assumptions and the expert opinion, a
conclusion in favour of either protocol appears to
offer significant value for money, as does the
overall weighted expected cost per life year. The
inconclusive outcome (B) does not provide positive
returns. The EICER of the trial would be
£2500–£4000 per life saved, or £85–£130 per life
year saved. This is low compared with nearly all
the current treatment costs and so would be cost-
effective. Were the trial to find in favour of the
field stabilisation protocol, but the shift away from
the current trend towards scoop and run did not
occur, or was very slow, then the cost per life saved
by the trial would be higher.
The trial, were it to reach either conclusive
outcome, would be clearly cost-effective when
considering predicted reductions in mortality. The
other outcomes measured in the trial may also be
important. Should the reduction in post-traumatic
incident mortality result in significantly more
disabled individuals surviving, or increase the
number of individuals requiring psychotherapeutic
interventions, then the subsequent utilisation of
health services would increase. In these cases the
quality of life is likely to be compromised, and the
cost per QALY is likely to be higher than the cost
per life year saved reported above.
The estimates reinforce the importance of effective
dissemination and the implementation of policy
supported by high-quality evidence. A number of
the experts stressed the importance of bodies such
as the Joint Royal College Ambulance Liaison
Committee, and the influence that such
organisations have on effecting change. However,
questions were raised about how quickly
ambulance services would introduce change, as
this was thought to be slow, and it was thought
that paramedics would be reluctant to change
their behaviour if the proposed change went
against their own intuition, personal preference or
a current trend. The growing importance of
clinical governance, nonetheless, should assist this
process. The framework and facilities for the
effective audit of practice against best evidence
should be important factors in effecting change. 
With the caveats above, the application of the
model to the proposed trial suggests that it offers
a good return. This report was written following
interviews with experts in July 1998, nearly 2 years
before the draft report of the results was available. 
Actual results of the trial
These results are based on the draft report
submitted to the HTA committee and received in
confidence by the PATHS team in June 2000.63
The main results were as follows.
  In total, 1309 patients were entered into the
study, 699 (53.4%) treated by paramedics
operating the fluids protocol A and 618 (46.6%)
operating the no-fluids protocol (scoop and
run) B. The randomisation worked well, with no
significant differences between the treatment
arms in incident characteristics, ambulance
performance times or patient and injury
characteristics, apart from slightly more
moderate and severe head injuries in the fluids
protocol group A (25.3 versus 20.3%).
  However, protocol compliance by the
paramedics was very poor. Only 31% of protocol
A patients received pre-hospital fluid (non-
compliance 69%). Eighty per cent of protocol B
patients were not given fluids (non-compliance
20%); that is, non-compliance overall was about
46%, with only about one-quarter receiving
fluids while about three-quarters did not. The
estimated odds ratio (OR) of being given pre-
hospital fluids when treated by the fluids
protocol compared with the non-fluids protocol
was only 2.09 [95% confidence interval (CI)
1.53 to 2.81].
  Of the 699 patients in the fluids arm A, 73 died
within 6 months (10.4%), and 60 of the 610
patients in the non-fluids arm B died (9.8%),
giving a crude OR for deaths when managed by
the fluids protocol A of 1.09 (95% CI 0.73 to
1.54). Excluding the 26 patients whose cause of
death may not have been trauma related
reduces the OR to 1.04 (95% CI 0.69 to 1.55).
Excluding 17 patients who may have been dead
at the time the ambulance crew arrived reduced
the OR to 1.04 (95% CI 0.70 to 1.53).
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unconscious at the scene did not significantly
alter these odds ratios.
  Health status questionnaires were sent to all 878
surviving patients identified within 7 months of
their accident, including an SF-36 questionnaire.
The response rate was similar in the two arms
(62.9 versus 64.6%). For all eight dimensions of
SF-36, protocol A patients (stabilisation)
reported a better score, but only one difference
was statistically significant and none was at a
level considered to be clinically significant.
  For subgroup analysis of each of eight
characteristics (ambulance service area,
presence of doctor on scene, paramedic contact
time, injury severity, emergency surgery, type of
injury, type of area, before or after protocol
cross-over), there was no evidence of any
difference in mortality rates or composite
outcomes.
  There were no economically significant cost
differences between the two groups.
  The researchers conclude that there is no
evidence that the fluid protocols are doing any
significant harm in these blunt instrument
trauma patients. They say that even though
they seem to be associated with an increased
risk of death, this could be remediable by
altering fluid protocols, although this
extrapolates beyond their result. This could be
because early fluids do little harm, or because
only one-quarter of patients are given them and
the protocols did not appear to alter this
proportion; that is, the actual treatment was
very similar in both arms and so the intention-
to-treat analysis is highly confounded, which
makes it difficult to draw any conclusions.
  The researchers recommend that ambulance
services should concentrate on avoiding
unnecessary delays and speed patients to
definitive care in hospital.
Their recommendations for further
research
  They estimate that patients given fluids spent
12–13 minutes longer on-scene than patients
not given fluids, but times were largely
unaffected by protocol (although as a result of
the poor compliance treatment was not strongly
related to protocol either). Scene time may still
be the critical issue and needs urgent
investigation.
  Further research should compare strict rather
than discretionary protocols and only
crystalloids should be permitted. Ways of
separating fluid infusion and scene time delays
should be sought.
  They conclude that the fluids issue remains
unresolved, and ask whether there is a similar
question for fluids in hospital pre-definitive
surgery care: are fluids appropriate in A&E? Do
the same questions apply about speed to
theatre? Can a blunt trauma trial to prevent
fluid resuscitation before theatre arrival be
organised?
Testing the model
Following our receipt of the draft report and with
the agreement of the authors, a copy was sent to
each of the experts, together with a second set of
questions (Appendix 5). Related to the three
possible scenarios considered, the outcome falls
clearly in the inconclusive scenario.
Ex post expert opinion
Change of practice
The A&E medical director said emphatically that
if protocols are to be used strictly then they must
be evidence based, disseminated and audited,
otherwise they are a waste of time as there will 
not be compliance. The implication was that this
was the reason why the trial protocols were not
adhered to, and why the trial does not provide
evidence for change. She said that the majority 
of services now accept that field stabilisation is
inappropriate for patients with haemodynamic
instability, and the priority is now for airways
management, oxygenation, ventilation and 
‘go’.
The other experts also said that the results would
not change practice and that a very high
percentage of services and paramedics use, and
should use, scoop and run.
Timescale of change
The experts thought this question to be redundant
as the results were unlikely to affect practice. They
said that practice has already changed, with
increased emphasis over the past couple of years
on the need for rapid conveyance to hospital once
airways had been freed and spinal immobilisation
carried out, and that this emphasis was likely to
continue and was already the most common
practice.
Protocols
The experts were asked whether the role of
protocols might be questioned outside the range
of the trial. One said that they might be, and the
other thought that this was not applicable given
the results.
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Although not appropriate in this instance, the
experts thought that the important methods of
dissemination would have been via the Joint Royal
College Ambulance Liaison Committee, via
training (both initial and updating) and protocol
usage.
Outcomes
One expert said that mortality was the most
important end-point, followed by length of stay in
the ITU, SF-36 at 6 months, broad disability and
finally SF-36 at 2 weeks. The other expert
clinicians thought that mortality was the least
likely outcome to be affected (although of 
course it is important) and thought that length 
of stay in ITU and the other quality of life 
issues were more relevant. For two of the 
experts this was a switch from their previous
opinion.
Overall comments
One expert said that there had been much
advance publicity about the study and that
changes had already been made, and that the
issue of protocol compliance is very important, is
always assumed but clearly does not happen. The
issue of extra on-scene time is important and
needs highlighting, as the study appears to
confirm that it conveys no benefits. The issue of
colloids versus crystalloids is now history, as most
services now use crystalloids.
Another expert said that the important thing to
come from the study was that it highlights and
validates the difficulties of research in this area,
and that the study has put down a marker. He saw
the problem of the study as that of confounding.
First, the trial confounds the role of the paramedic
with that of fluid replacement, and putting these
two variables together in the trial was bound to
result in insignificant results as they are two
different effects. He thought that there was also
confounding due to lack of stratifying by
competence. As paramedics are acting in an
emergency situation they will do what they think is
best in the circumstances and/or what they can do
best. They would feel compelled to intervene if
they thought it necessary, but if they were not
sufficiently skilled at cannulation they would not
wish to take responsibility for it. So, he thought it
important that paramedics in such a trial need to
be well trained and skilled, taken into confidence
and be in agreement with the trial. He also noted
the unfortunate and ironic fact that patients who
are in the greatest need of fluid replacement,
those who have lost most blood, are the most
difficult to intubate, so the patient most in need is
least likely to receive fluid replacement. He
thought that the results as such were likely to
reinforce existing practice and not change
anything. He agreed with the authors that a study
of fluid replacement needs to be done, that the
question is unresolved and is central to
predefinitive care, and needs to be evaluated
independently from paramedic skills. He made
the observation that UK protocols tend to follow
US research, which does not capture the unique
UK circumstances. Blunt trauma, which is most
common in the UK, is less sensitive to intervention
than is sharp trauma, which is most common in
the USA. In the former, victims tend to die quickly
or heal themselves, so trials for blunt trauma need
larger numbers than do trials for sharp injuries.
He concluded that although this study has not
moved the knowledge base on, it has nevertheless
moved on the research by identifying its practical
problems. Early attempts at research are inevitably
less than perfect. He feels that the NHS
concentrates too much on service, to the
detriment of training and research. He applauded
this work for paving the way for future research in
the area.
Another expert expressed concern about the trial’s
evidence of paramedics’ poor compliance with
protocols.
Testing of ex ante predictions
The results of the trial fall clearly into scenario B
(inconclusive) and as such are unlikely to influence
current practice. The cost of the trial is not
recouped by reduced service costs or added
benefit, although there is likely to be some
valuable research experience.
All of the experts agreed that the trial had
conferred some knowledge benefits, particularly
relating to the non-compliance with protocols and
the need to investigate this. There was also a
strong plea from the A&E consultant expert that
the incremental nature of research should be
recognised, that methodological mistakes should
be acknowledged and that further research in this
area should be encouraged. The need to examine
the role of fluid replacement in predefinitive care,
whether prehospital or in A&E before surgery, was
expressed strongly by the two clinicians, and that
it should be examined in a situation where it is not
confounded with the paramedic’s role.
Conclusions
The results were clearly affected by the lack of
equipoise, as the evidence of the benefit of
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particularly over the past few years. This was not
the only reason for the lack of protocol
compliance, however, as there was also not
inconsiderable non-compliance of 20% with the
scoop and run protocol, which bucked the trend,
so a similar proportion of paramedics in both
arms carried out scoop and run despite the
protocol requirements, probably as they would
have done without the protocol. There was some
indication that non-compliance was greater in one
of the research areas and could be related to
entrenched preference, practice or skill; it was also
weakly related to case-mix and so to some degree
to the relevance to the individual case.
The overall conclusion is that the question of fluid
replacement use is one that requires answering by
research in the UK setting and that there was
good reason to fund this study area. That the
study has not answered the question was due
partly to factors outside the control of the
researchers or knowledge of the funders: the
strong movement towards favouring one protocol,
and the paramedics’ non-adherence to protocols.
These elements were picked up to some extent by
the experts at the ex ante interviews, although this
was after the funding. The results and problems
with the execution of the trial emphasise the
importance of knowing the baseline practice
situation, making sure that key personnel are on
board with the study and monitoring for, rather
than assuming compliance; non-compliance is a
common organisational problem in managing
RCTs. The study’s problems tend to confirm the
strength of the Bayesian approach in health-
services research33 to allow for a background of
changing knowledge and practice.
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This chapter presents the third case study using
the model. Again, the modelling exercise will
analyse the expected benefits from the research
project, and relate these to the likely costs
associated with likely implementation of results
and of undertaking the trial itself.
Project summary
The project ‘Early surgery or observation for small
abdominal aortic aneurysms?’ known as the MRC
small abdominal aortic aneurysm (AAA) trial, was
funded by the UK MRC and the British Heart
Foundation with a series of grants. It was a
multicentre RCT of the outcomes of early surgery
compared with a period of ultrasound surveillance
for patients aged 60–76 years with small
asymptomatic AAAs of between 4 and 5.5 cm.
Study details
Aortic aneurysm (a balloon-like swelling of the
aorta) is a common condition; the prevalence in
the population over 50 years is estimated from
autopsy studies to be 3% and it is the third most
common cause of sudden death. Nearly 1000
people die owing to aortic aneurysms in the UK
each year, and a further 2000–3000 undergo
successful aortic grafting each year. Mortality
associated with elective surgery is now likely to be
less than 5%, but post-emergency surgery
mortality is high (40%) and numbers admitted for
ruptured aortic aneurysms continue to rise.
Most surgeons would operate on an aneurysm
over 6 cm in diameter, and few would operate on
an aneurysm under 4 cm in diameter, owing to the
different probabilities of rupture in each case.
However, a grey area existed concerning
asymptomatic aneurysms of sizes between 4 and 
6 cm, and no consensus existed on the
management of such AAAs.
The study used ultrasound scanning to determine
the size of the asymptomatic infrarenal aneurysm.
If it was less than 4 cm, the patient was observed,
with a view to randomisation should the aneurysm
grow. If it was between 4 and 5.5 cm and the
patient was fit for surgery, then the patient was
randomised into either an observation or a
surgery group. If it was greater than 5.5 cm the
patient was offered surgery. The observation group
was seen every 6 months, but those with an
aneurysm diameter between 5 and 5.5 cm were
observed every 3 months.
An economic evaluation was undertaken. The 
costs of aortic grafting are considerable, as are the
costs of regular observation. Furthermore, an
unknown proportion in the observation group
would require surgery for aneurysms that
increased in size. Quality of life was also
considered to be important, as those in the
surgical group might be expected to return to
normal quality of life within 6 months, while 
those in the observation group might display
anxiety about possible aortic rupture, and as such
might limit their activities. Quality of life was
measured by the generic Medical Outcomes 
Study (MOS) instrument administered at the local
level.
Aims of the AAA trial
  To compare the mortality associated with early
operation or observation in the management of
small asymptomatic AAAs.
  To compare the costs and usage of NHS
resources for patients having each treatment.
  To determine the growth and rupture rates of
small AAAs.
  To investigate factors associated with the
accelerated growth and rupture of small aortic
aneurysms.
  To investigate, across Britain, how 24 hour 
and 3 day mortality rates for elective aneurysm
surgery vary according to age, gender,
aneurysm size and cardiovascular risk factors.
Health Technology Assessment 2003; Vol. 7: No. 20
39
© Queen’s Printer and Controller of HMSO 2003. All rights reserved.
Chapter 6
Case study 3: MRC small aneurysm trial of early 
surgery or observation for small abdominal 
aortic aneurysmsEach operation cost about £10,000 (in 1990), and
so there exists an urgent need for rational
decision-making with regard to the management
of small asymptomatic AAAs. The results of the
trial will dictate the future of aneurysms screening
programmes and the management of small
aneurysms.
Timing of the trial
The funding application was submitted in August
1990 (economics funding application in February
1991) for a start date of January 1991 (April 1991)
and expected completion in October 1998; it was
published earlier than expected, in November
1998. First interviews were carried out in
December 1998 and second interviews in July
2000.
Data from experts
Four experts were approached for their opinions:
two cardiovascular surgeons, a director of public
health and a health economist with experience in
undertaking economic evaluations of
cardiovascular services. All agreed to participate,
except for the director of public health who passed
it to a junior colleague. The latter was thought
inappropriate for the purposes of the study and,
given the experience from the previous cases that
a close familiarity with the technical and service
aspects was necessary to address the questions
precisely, and that this was a highly specialist
topic, no further attempts were made to include a
purchaser in the expert ‘panel’ for this study.
Between approaching the experts and carrying out
the interviews the results were published in the
Lancet. This happened earlier than the authors
had been led to expect. A decision was made to
proceed as before, sending them a set of four key
papers64–67 available at the time of funding and an
outline of the trial, and asking the experts to
answer the initial set of questions as at the time of
funding, as for the previous cases, ignorant of the
results of the trial (Appendix 6). The authors
readily acknowledge the limitations of this
suspension of knowledge. One month later the
experts were sent the results68,69 and asked the
second set of questions (Appendix 7).
They were asked how, at the time of funding in
1990, they would have expected the treatment of
small AAAs in patients aged 60–76 years to have
developed had the trial not been funded, what
proportion would have undergone early elective
surgery in 1990 and how would this have
developed over the subsequent 10 years had the
trial not proceeded.
All agreed that in 1990 almost all such aneurysms
(some 95%) would have been treated by elective
early surgery. With the development of ultrasound
and the known mortality risk of elective surgery
there would have been some slight movement
towards more conservative management (watch
and wait) over the next 10 years to possibly 10%,
reducing those having surgery to about 90%.
There might have been variation in surgery
depending on age and size of aneurysm, with
younger patients and those with larger aneurysms
more likely to have received surgery. They thought
that on the whole surgeons would think it safer to
operate.
If the trial found in favour of early elective surgery
this would confirm current and established
practice, and all of the experts anticipated that
this would lead to a further increase in the
proportion receiving surgery, possibly up to 95%.
The actual change would depend on the margin of
difference between the procedures, and other
developments such as progress in and costs of the
new endovascular techniques. They thought that
surveillance for smaller aneurysms would be likely
to continue.
Were the conclusions of the trial ‘inconclusive’, all
three thought that there would probably be little
change in practice, unless there was an indication
of no benefits of surgery. Response would depend
on why the trial was inconclusive, and such a result
might lead to more research, as RCTs are very
unusual in surgery and there has been a high level
of ‘ownership’ of this trial among clinicians. It was
thought that this result would possibly lead to a
move towards 15% surveillance and 85% surgery
over the following 5 years.
Were the trial results to favour surveillance, all of
the experts expected a change in practice towards
surveillance. The impact would be less than if the
result favoured surgery, as surgeons are more
confident operating and it would be against the
usual accepted practice. The shift was expected to
be to 50% surveillance over the following 5 years.
Outcome measures
The main outcome measure, which was all-cause
mortality, was thought to be the right one and the
most important outcome, although one consultant
thought it unlikely to show a significant change as
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and most of these are sudden death from
undiagnosed aneurysms. All thought that quality
of life was important, but did not think that the
MOS was likely to be sensitive enough to pick up
differences; it was thought that anxiety was the
most likely to be significantly different between the
groups, but was only a small component of MOS.
However, it was thought that surgeons were not
likely to be swayed by quality of life differences. All
thought that health-service costs were important
and that the health-service perspective was the
right one to influence policy (patient costs were
not taken into consideration).
Threshold levels
The experts were asked what barriers and
threshold levels there might be concerning
adoption of the more cost-effective management
protocol, including what reduction in mortality,
cost or quality of life might be necessary to trigger
a change in practice. Two of the experts thought
that a 5% difference and one thought that a 7–9%
difference in mortality would trigger change. All
thought that compared with mortality, costs would
be considered of little importance unless they were
over £2000 per patient. Quality of life differences
would need to be very high at 20–30% differences.
Probability of trial outcomes
The experts were asked what they thought were
the probabilities of the different outcomes of the
trial. There was a considerable difference of
opinion. The probability of an outcome in favour
of surveillance was considered to be about 25%
(20%, 25% and 30%); in favour of surgery 5%,
20% and 60%; and inconclusive 20%, 50% and
70%. These ranges suggest that the experts were
not influenced by or cognisant of the actual
results; these ranges, together with equal
weightings, will be used in weighting the results.
Model parameters, results and
discussion
It was decided that, with the rapid development of
other techniques such as endovascular surgery, a
period of 5 years would be appropriate for
implementation. Therefore, the costs and benefits
of treatment of patients presenting over the 5
years following the results, and their treatment
and its outcome for a 5 year period (making 10
year follow-up altogether), were calculated and
discounted to 1990. The cost per operation was
taken from the literature as £10,000, and costs of
outpatient ultrasound surveillance as £75 per visit.
As the average rate of growth of an aneurysm of
this size is about 0.5 cm per year and elective
surgery would be offered for aneurysms reaching
over 5.5 cm, it was estimated that half of the
observation group would receive surgery after
about 2.5 years. The size of the UK population
aged 60–76 years with detected aneurysms of this
size (in the absence of screening) is about 2000
per year. It is assumed that without the trial 90%
would have surgery and 10% surveillance, with
half of the latter requiring surgery within 5 years.
Table 14 sets out the scenario assumptions based
on the experts’ opinion.
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TABLE 14 Scenario assumptions
Trial outcome Implementation scenario
A (favouring early surgery)
Trial shows that early surgery is effective and cost-effective:
• mortality 29% surgery
36% surveillance
• favourable quality of life
A
Increase in early surgery from 90% to 95% of presenting
patients within 5 years:
• half of the surveillance patients would receive surgery
within 5 years
B (inconclusive)
No significant difference in mortality or quality of life
B
Following the trial, there is a small switch against surgery
from 90% to 85% over 5 years:
• half of the surveillance patients would have surgery within
5 years
C (favouring surveillance)
No significant difference in mortality (29% both forms of
care); 20% higher quality of life for surveillance patients:
• significantly lower costs for surveillance
C
Following the trial there is a shift against surgery from 90%
to 50% over 5 years:
• half of the  surveillance patients would have surgery
within 5 yearsThe costs of the trial and the costs and benefits of
the implementation following each trial outcome
were calculated using the assumptions above, and
are presented in Table 15 for these three scenarios.
In each case the costs and benefits that would have
occurred without the trial were identified in order
to calculate the net implications of the trial, and
the costs and benefits with and without the trial
are presented for each scenario, along with the net
costs and net benefits of the trial and finally the
incremental cost per life saved.
An outcome favouring early surgery would result
in an estimated net discounted cost of £2.1 million
over 10 years for a net saving of about 12 lives,
giving a cost per life saved of about £180,000. An
inconclusive result is likely to lead to a net cost of
£0.23 million over 10 years for no benefit of lives
saved. An outcome favouring ultrasound
surveillance would result in a net saving of some
£3.36 million for some 20% quality of life benefit,
but no significant net change in survival.
The net outcomes have been combined in a
probabilistic framework to summarise the overall
expected value of the trial. Probability weightings
are based on the expert means, expert highest
values for surgery, expert lowest values for surgery
and equal weightings for each scenario; weighted
results are given in Table 16.
For combinations 1, 3 and 4 there is a small saving
in costs of one-third to £0.85 million over 10
years, together with a saving of up to four lives.
For combination 2, 60% probability favouring
surgery, there would be a cost of £840,000 and an
expected saving of some seven lives, giving an
expected cost per life saved of about £117,000
(per life year of possibly £7500). The number of
lives saved is not significantly different from zero
in any of the scenarios.
Conclusions
This case study report could represent advice to a
research funding body about the likely returns to
the proposed research. The conclusions relate to
the likely payback in terms of costs and benefits,
but also to the research design and issues around
dissemination and likely implementation.
The main conclusion from this study is that the
expected payback to the trial is marginally
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TABLE 15 Cost and benefit calculations for the UK 
Scenario A Scenario B Scenario C
Trial result: For surgery Inconclusive For surveillance
Without trial
Net cost (£ m) 45.457 45.457 45.457
Survivors 5442 5496 5496
Trial
Trial cost (£ m) 0.987 0.987 0.987
Following trial (10 years)
Cost (£ m) 46.616 44.699 41.110
Survivors 5454 5496 5496
Net trial implications
Net costs (£ m) 2.146 0.229 –3.36
Lives saved 12 0 0
Cost per life saved £178,800 ––
TABLE 16 Expected weighted costs and benefits (probability weightings)
Combination 1:  Combination 2:  Combination 3:  Combination 4: 
Surgery 28% Surgery 60% Surgery 5% Surgery 33%
Survival 42% Survival 15% Survival 70% Survival 33%
Expected costs (£ m) −0.742 0.841 −2.187 −0.328
Expected lives saved 3.36 7.20 0.60 4.00
Expected cost/life Dominant £117,000 Dominant Dominantpositive, with expected small savings in both life
and costs. Should the outcome be inconclusive
there would be a likely cost of about a quarter of a
million pounds for no benefit; a finding in favour
of surveillance would result in a net discounted
cost saving of about £3.4 million, while a finding
in favour of early surgery would cost £2.1 million
over 10 years, saving some 12 lives at a cost of
£175,000 each, with an expected normal lifespan
and quality of life, meaning a cost of about
£20,000 per life-year saved.
Overall, the conclusion would be marginally in
favour of the trial taking place, with a small but
non-significant benefit from the trial. The benefits
are likely to be low, partly because of the relatively
small relevant population, the length of the trial
and its cost, and because the cheaper care
(surveillance) is unlikely to lead to a significant
reduction in mortality but is likely to lead to
surgery within 5 years for half of the patients. The
length of the trial, although necessary, also
reduces its likely relevance, as it may be overtaken
by new surgical techniques of higher efficiency and
lower cost. The design and outcome measures are
considered appropriate, but a stronger measure of
anxiety could be included.
Actual results of the trial
The results of the trial were published in two
papers in the Lancet in November 1998; one
reporting the mortality results68 and the other the
health-service costs and quality of life.69
The main results were as follows:
  In total, 1090 patients aged 60–76 years with
symptomless AAA 4.0–5.5 cm in diameter were
randomised, 563 to undergo elective surgery
and 527 ultrasonographic surveillance. Patients
were followed for a mean of 4.6 years. Surgical
repair was recommended if the diameter
exceeded 5.5 cm in the surveillance group. The
primary end-point was death. Analysis was by
intention to treat.
  Both groups had similar cardiovascular risk at
baseline; 93% of patients adhered to treatment
and 309 patients died during follow-up.
  Mortality did not differ significantly between
the groups at 2, 4 or 6 years. Age, gender and
initial aneurysm size did not modify the overall
hazard ratio.
  The overall hazard ratio for all-cause mortality
in the early surgery groups compared with the
surveillance group was 0.94 (95% CI 0.75 to
1.17, p = 0.56). The 30 day operative mortality
in the early surgery group was 5.8%, which led
to a survival disadvantage for these patients
early in the trial, countered by lower mortality
later, so the cross-over point was at about 3
years.
  For patients in the surveillance group the
median time to surgery was 2.9 years (when the
aneurysm diameter had grown to more than 
5.5 cm, increased by more than 1 cm per year,
or was tender or ruptured).
  There was some indication of a non-significant
higher mortality rate for those under 72 years
in the surveillance group compared with the
surgery group, but a lower mortality rate for
those over 72 years. There was also a non-
significant trend in relative mortality with
diameter of aneurysm, favouring surveillance
for aneurysms under 4.5 cm and surgery for
those over 4.5 cm.
  The mean cost of treatment in the early surgery
group was significantly higher than that for
ultrasonographic surveillance, at £4978 versus
£3914, a difference of £1064 (95% CI £799 to
£1328). This finding was robust for a range of
assumptions.
  Health-related quality of life was generally
similar 12 months after randomisation for the
two groups, but patients who underwent early
surgery reported positive improvement in
current health perceptions and less negative
change in bodily pain.
  The research team conclude that
ultrasonographic surveillance for small AAAs is
safe, that early surgery does not provide a long-
term survival advantage and that their results
do not support a policy of open surgical repair
for AAAs of 4.0–5.5 cm.
Testing of the model
Copies of the two papers in the Lancet were sent to
each of the experts, together with a second set of
questions (Appendix 7). Of the three scenarios
considered, the published outcome agrees closely
with that favouring surveillance.
Ex post interviews with experts: their
predictions of the effect of the trial
results on subsequent policy
Implementation
All three experts agreed with the authors that
there should be a shift towards the use of
ultrasound. One said that surveillance should be
used for 5 years and then assessed nationally for
mortality, rupture and natural history. He said that
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technology to endovascular surgery down to 4 cm
if that technique becomes cheaper. Another said
that although some surgeons are saying this, it is
illogical and not supported by the findings. One
expert thought that the researchers’ Lancet
summary was somewhat misleading and that if
surgeons wished to ignore their conclusions there
is evidence in the paper that could be used to
continue existing practice; that is, to use early
surgery for younger patients and larger
aneurysms, with surveillance for older patients
and smaller aneurysms, and the extra cost of only
£1000 would not be a likely restraint. However, all
thought that the study would be highly respected
and widely owned, as many of the UK vascular
surgeons took part in it.
Modelling ex post predicted
outcomes
The ex post expert consensus was for a move
towards more use of surveillance. However, it was
not expected that this would be 100%, but more
likely to be about 50% (from 10%) over about 5
years. This was consistent with their ex ante
predictions for an outcome favouring surveillance.
If the move to surveillance was 50% over 5 years
as the experts predicted, then the discounted 10
year cost saving would be £0.954 million, resulting
in a non-significant net cost of some £0.033
million (–£0.271 million to £0.203 million). A
move to a full 100% surveillance over 5 years
would result in a discounted 10 year cost saving of
about £2.416 million which, net of the cost of the
trial, would result in a net saving of £1.43 million
(£0.38 million to £2.03 million).
The ex post returns are less than predicted for the
outcome, because the cost of surgical repair
estimated during the trial was less than that
estimated in the literature before funding. Overall,
payback, estimated both ex ante and ex post, is low
and non-significant owing to the relatively small
population and the high proportion of those
having surveillance later needing surgery.
In conclusion, the ex post predicted outcomes are
very similar to the ex ante predictions and imply
that the predicted 10 year savings will cover the
cost of the trial by a small margin, but result in no
significant change in expected mortality. It is
unlikely that this study would have qualified for
competitive funding on the grounds of likely
payback.
Case study 3: MRC small aneurysm trial of early surgery or observation for small abdominal aortic aneurysms
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During the course of the study the authors
received a request to apply their model to an
application for funding for a large, randomised,
double-blind multicentre trial, the UK-MS study: a
trial of β-interferon (IFN-β) for the treatment of
multiple sclerosis (MS), submitted to the HTA
programme in the UK.70 The results of this
analysis are reported in addition to the case
studies, as it provides an illustration of the use of
the model.
The primary aims of the proposed trial were to
evaluate the safety, efficacy and tolerability of 
IFN-β and of some other new treatments for MS.
In addition, some limited information on resource
use was to be collected ‘to inform health economic
analyses’. The trial was planned to last for 10
years. The UK HTA programme approached the
authors to undertake an analysis of the likely
payback from the proposed trial. This chapter
outlines that assessment of the likely value of the
proposed £20 million trial as carried out in
January 1999.71 It goes on to consider whether
any subsequent evidence from other studies or
changes in the policy-making environment might
have changed the recommendations.
Evidence available at the time
At the end of 1998, available evidence consistently
pointed to some small clinical benefit to MS from
IFN-β. Published trials had each added to the
evidence that there does appear to be a
statistically significant difference between standard
treatment and IFN-β in terms of delayed
progression and lower relapse rates.72–75 The
initial evidence was for relapsing remitting (RR-
MS) patients, and later evidence suggested that
there might also be benefit for secondary
progressive (SP-MS) patients.75 However, the
clinical importance of these differences was
uncertain (not least because of the difficulties in
conducting therapeutic trials in this area),76 as was
the effect of the observed differences on the
quality of life of an MS patient compared with 
the effect of other, non-clinical interventions.
There had been no economic evaluation
undertaken as part of a large randomised trial of
IFN-β in the treatment of MS at the time the
proposal was made. The debate on cost-
effectiveness relied on modelling studies.77–82
These studies had produced widely differing
absolute values for the possible cost–utility ratio.
Such variation is always likely to occur in cost-
effectiveness ratios where the numerator
(incremental cost) is large and the denominator
(incremental effect) is very small. Despite this
absolute variation, the various estimates of
cost–utility ratios were consistent in policy terms in
that none had, even in a sensitivity analysis,
produced figures that would suggest that IFN-β
for MS could be deemed cost-effective by normal
health-service standards. To develop the evidence
base further, we used the effectiveness data from
the European Study on the use of IFN-β in SP-MS
patients75 in a published decision analysis model81
to estimate the QALYs that would be gained from
the costs of the trial and the likely levels of future
prescribing that were judged would follow from
the trial results.
A large definitive trial was proposed, although at
that stage not precisely specified, to establish cost-
effectiveness. The PATHS team was asked to
evaluate the likely payback to such a trial. Summary
results of this analysis and its conclusions are
presented here. 
‘Payback’ analysis and
recommendation
Before examining the value of conducting a trial,
it was necessary to examine the counterfactual:
what was likely to happen to the level of
prescribing during the next 10 years if the trial
did not take place. The situation in the UK at that
time was that only 1.5% of MS patients were
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Chapter 7
An application of the PATHS model: an assessment 
of the likely payback from a proposed UK trial of
β-interferon for the treatment of multiple sclerosisreceiving the drug,71 in spite of well-organised
information supplied by patient interest groups
and of high patient expectation of the use of 
IFN-β. This contrasted starkly with the levels of
prescribing in most other European countries
(6–23%) and the USA (16%). Prescribing was
relatively very low in the UK owing to the terms of
the UK licence, the need for prescribing by a
consultant neurologist and local allocation of very
limited funds for IFN-β.
Expert clinicians, an economist and a
statistician/epidemiologist, all of whom had
worked closely in this research area, were
consulted to inform the assumptions. 
It was hypothesised that future levels of
prescribing in the UK might be altered by:
  a widening of the terms of the UK licence
following the results of, what were at that time,
recently published and ongoing trials showing
benefit for other subgroups of MS patients in
addition to RR-MS patients
  the expiration of the current patent for IFN-β,
and the possibility of lower price generic
products
  the availability of new products for treating MS,
some of which might be used in combination
with, or as an alternative to, IFN-β
  most importantly, the policy position of the
Department of Health and of individual
commissioners of healthcare that might be
influenced by any or all of the three factors
listed above.
It was concluded that the above pressures were
likely to lead to an upward trend in prescribing
rates. However, the size of this increase would
ultimately depend on the continuing
determination of central and local policy makers
to act to constrain the availability of IFN-β in the
absence of firm evidence of an acceptable cost-
effectiveness ratio.
An application of the PATHS model
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TABLE 17 Principal possible outcomes of the trial of IFN-β
Trial outcome Prescribing outcome
A
No net overall clinical benefit and not cost-effective:
• net treatment costs over 10 years: £78,000
• QALYs gained over 10 years: 0 
(infinite cost per QALY)
A
Following the trial, prescribing reduced to very low levels:
• RR-MS: 280 patients
• SP-MS: 400 patients
B
Net overall clinical benefit but not cost-effective:
• net treatment costs over 10 years: £78,000
• QALYs gained over 10 years: 0.07 
(approx. £1 million per QALY)
B1
Department of Health and health authorities impose stricter
restraints on the prescribing of IFN-β: prescribing is
reduced in the light of cost-effectiveness information:
• RR-MS: 1800 patients
• SP-MS: 2500 patients
B2
Department of Health and health authorities impose no or
weak restrictions on the prescribing of IFN-β: IFN-β is
prescribed to a high proportion of those qualifying within
the licence.
• RR-MS: 12,000 patients
• SP-MS: 10,000 patients
C
Net overall clinical benefit and cost-effective; based on most
optimistic assumptions:
• net treatment costs over 10 years: £50,000
• QALYs gained over 10 years: 0.12 
(approx. £400,000 per QALY)
C
Prescribed to a higher proportion of those qualifying within
the licence:
• RR-MS: 16,000 patients
• SP-MS: 14,000 patients
Likelihood of outcomes
Outcome B: considered to be most likely (80% probability); B1 or B2 depends on Department of Health/NHS policy
Outcomes A and C: considered to be unlikely (probability of 10% each)The potential payback from the proposed trial was
considered against this background using
previously published frameworks of Buxton and
Hanney9 and Townsend and Buxton.16 The latter,
a precursor to the PATHS model as described in
this report, used a quantitative analysis to assess
the likely value of a proposed MRC trial of long-
term HRT. It examined three main scenarios,
reflecting different possible trial outcomes and
their resulting prescribing levels. Building on this
and the early development of PATHS, we similarly
looked at three possible outcomes for the MS trial
and what would be likely to follow from them in
terms of clinical policy for MS in the UK over a 20
year period (10 year trial and 10 years post-trial).
(Full details of the calculations summarised here
are contained within the original report to the UK
HTA programme.71) 
It was assumed, based on the expert opinion, that
if the trial were not to proceed, then the number
of MS patients prescribed IFN-β would increase
over time. The model assumed that over 10 years,
the number of RR-MS patients receiving IFN-β
would increase from the then current position
(approximately 1200 patients) to 2400 patients,
and that this level would remain constant for the
subsequent 10 years. It was also assumed that 
IFN-β would be gradually made available to 3400
patients with SP-MS over the next 10 years, and
again that this level would hold over the
subsequent 10 years.
The principal possible outcome scenarios of the
proposed trial are set out in Table 17, and the costs
and benefits for each with or without the trial (the
counterfactual) in Table 18.
For each of these scenarios estimates were made of
the costs of the trial, the benefits that would arise
during the trial, the cost of the therapy following
the trial and the health benefits that would arise
from that. In each case the costs and benefits that
would have arisen without the trial were netted off.
This gives the net implications of the trial, which
are presented in terms of net costs, net QALYs
and the implied cost per QALY of the trial and its
resulting prescribing (Table 18).
Under only one of these scenarios can the
proposed trial be justified on cost-effectiveness
grounds. This (scenario A) makes the unlikely
assumption that the trial shows IFN-β to have no
net benefit to patients, and that as a result its
prescribing would be discontinued.
In scenario A the trial has no effect on QALYs (the
intervention is found to be ineffective), but leads
to a net saving from a subsequent reduction in
prescribing. Scenario B1 results in a saving from
undertaking the trial of just under £100 million,
which is offset by a reduction in benefits to
patients of 105 QALYs (equivalent to a cost saving
per QALY foregone of approximately £900,000).
In contrast, scenario B2 (with a weak policy)
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TABLE 18 Cost and QALY calculations for principal possible outcomes
Scenario A Scenario B1 Scenario B2 Scenario C
Without trial (20 years)
Net therapy cost (£ m) 725 725 725 465
Benefits 0 651 651 1115
During trial (10 years)
Trial cost (£ m) 20 20 20 20
Net therapy cost (£ m) 273 273 273 175
Benefits (QALYs) 0 245 245 420
Following trial (10 years)
Net therapy cost (£ m) 53 335 1716 1500
Benefits (QALYs) 0 301 1540 3600
Net trial implications
Net costs (£ m) –379 –97 1284 1230
Net benefits (QALYs) 0 –105 1134 2095
Cost/QALY of trial and resulting prescribing No change in  £924,000 £1.13 m £423,000
QALYs, but saving 
of £379 m
Judgement of probability of outcome 10% 80% B1 or B2 depends on  10%
Department of Health policyresults in an increase in costs of £1284 million, to
be offset against 1134 QALY gains following the
trial. Therefore, the cost per QALY of the trial in
this situation is £1.13 million. Finally, if scenario C
were to arise, in which the cost-effectiveness of the
intervention were shown to be much more
favourable, then the cost per QALY of the trial
and subsequent prescribing would still be over
£400,000. 
Arguably, the least useful outcome of the trial
would be scenario B: the production of strong
independent evidence of some patient benefit, in
combination with further, stronger evidence that
IFN-β is not cost-effective. The report suggested
that this outcome might leave policy makers in the
difficult situation of being unwilling to act on the
latter because of the former. Based on expert
opinion, and in line with all current evidence,82–84
the most likely outcome of the proposed trial was
judged to be B: that the trial would show some net
overall clinical benefit at a very considerable net
cost.
Each of these scenarios was an attempt to consider
what might happen from a broad range of detailed
possibilities. However, the analysis indicated that
the policy conclusions were not sensitive to detailed
assumptions. The only attractive (cost-effective)
outcome was one in which the evidence was such
that it could lead to a reduction in prescribing.
This could follow from evidence that there was no
net overall clinical benefit or that the net effect for
patients was negative. Neither seemed likely given
existing evidence. The question then became
whether a trial producing stronger evidence of a
small effect at a very high cost per QALY would
lead to a reduction or an increase in prescribing.
This would depend on the policy response from
the government department.
The benefits of the proposed trial would be highly
dependent on the policy adopted both during and
after the trial, and the extent to which there was
willingness to restrain prescribing of IFN-β based
on cost-effectiveness information. Unless
prescribing restraint could be firmly maintained
the trial would probably not be feasible.
None of the levels of cost per QALY that were
calculated approached conventionally acceptable
levels. Indeed, on the available evidence no likely
way could be seen in which this trial and its
resulting impact on therapy could achieve a
conventional threshold level of cost per QALY.
The most favourable net cost per QALY of the
trial plus resulting prescribing exceeded £400,000
per QALY, and was based on the scenario that the
trial would find strong evidence of a net overall
clinical benefit and that IFN-β would be found to
be much more cost-effective than suggested by any
existing analysis. The likelihood of this outcome
was judged to be no more than 10%. The more
likely scenario suggested a cost per QALY of
around £1 million.
If the current evidence base was inadequate for
policy, it was important to consider what were the
main areas of uncertainty that needed to be
addressed. It was clear that a trial to increase the
precision of the estimate of small differences in
clinical effectiveness was not needed. Rather, any
trial to improve the evidence base for policy
makers needed to address the key policy question
of cost-effectiveness. There was no need for
precision about how effective IFN-β was, if under
all plausible circumstances, it was not likely to be
cost-effective.
The assessment also considered other categories of
possible payback.9 In particular, it was recognised
that the proposed trial would generate knowledge
benefits of wider relevance to the understanding
of MS, particularly on disability and quality of life,
of the non-healthcare costs associated with MS,
and information to assist in the interpretation of
the long-term implications of short-term
indicators of disease progression.82 Although each
of these would be of value in interpreting future
research, it was argued that each could be
achieved through other less expensive studies.
Subsequent research and policy
decisions
The UK HTA programme did not fund the
proposed trial. It did, however, commission, in
collaboration with other interested parties
including the MS Society and commissioners of
healthcare, five reviews, the first four of which
have been published, of the evidence on:
  disease-modifying drugs83
  the natural history and epidemiology of MS:
modelling of the burden of morbidity and
disability85
  the role of specialist nurses84
  treatment for fatigue86
  the management of pain and spasticity (not yet
published).
Each of these reviews is being considered by the
National Institute for Clinical Excellence (NICE)
An application of the PATHS model
48Health Technology Assessment 2003; Vol. 7: No. 20
49
© Queen’s Printer and Controller of HMSO 2003. All rights reserved.
as it prepares its guidelines for the management
of MS.
In the meantime, NICE was asked in August 1999
by the Department of Health and the National
Assembly for Wales to appraise IFN-β/glatiramer
for MS. There followed a prolonged process of
appraisal, appeal and reappraisal, which included
the commissioning of further economic modelling
in the context of the Appraisal Committee’s
doubts about the cost-effectiveness of these drugs.
Finally, early in 2002, NICE issued its appraisal
determination, which confirmed their view that
the drugs could not be recommended because of
their poor cost-effectiveness.87 Based on the
additional modelling, NICE reported the cost per
QALY gained over a 20 year time frame to be
between £40,000 and £90,000. The Department of
Health responded to this conclusion by
announcing a ‘risk-sharing’ arrangement that
would, following reductions in the price of the
drugs, make the drug available to appropriate
patients, while those patients would be monitored
to ‘confirm’ the cost-effectiveness of the drugs.88 If
this cost-effectiveness did not reach a pre-agreed
level, then the companies would have to reduce
further the costs to the NHS.
Conclusions
The conclusion was that it was highly unlikely that
IFN-β for MS was cost-effective, although it was
conceivable that the drug could be cost-effective if
precisely targeted at groups of patients who would
be most responsive to the drug, if such could be
identified.89–91 Forbes and co-workers92 looked at
cost utility in a possible subgroup of ambulatory
SP-MS patients with more active disease, but still
estimated a cost per QALY of over £800,000 (95%
CI £161,000 to infinity). The subsequent detailed
cost-effectiveness modelling has produced lower
estimates of the cost per QALY but, at the then
prevailing prices, still not within normally
accepted limits for the NHS.
It was also concluded that the proposed trial
would not be cost-effective, and the analysis
reminds us that we should no more presume that a
technology assessment will be cost-effective than
will a technology itself. HTA funding should be
directed to those areas in which timely results are
likely to influence policy making. This requires an
analysis that considers both the theoretical value
of information and the likely behavioural response
to it. Formal Bayesian analysis of the value of
information may offer a way to improve our
estimates of the former; better political, science-
based understanding of what influences policy
making may help to improve our estimates of the
latter. T
he PATHS study set out to synthesise a
methodology for assessing the likely payback
or returns to proposed health technology
assessments and to apply this methodology in case
studies. It was recognised from the outset that a
full formal testing of the methodology was
impracticable in terms of timescale and resources.
Such a formal test would require assessment
before, but independent of and hidden from the
decision to fund a series of proposed projects, and
then follow-up of the actual payback from these
projects over an extended period after the
completion and dissemination of the research. To
assess the impact of the method in practice would
involve an even more extensive and elaborate
study, comparing a research programme that used
the proposed methodology with one that did not.
This would take several decades. The more
modest aim here is, therefore, to demonstrate the
potential value of a practical and feasible
approach, and to indicate the sort of impacts that
it might be expected to have.
The approach developed here emphasises the
benefits from the implementation of the results of
assessment, and estimates the costs and benefits
that may flow from alternative outcomes of a
research project or an area of research. Expert
opinion is used to inform the decision analysis
model, in a way that builds on and formalises the
usual process of incorporating expert input from
potential users of research into the decision-
making about the research funding. It uses this to
consider the likelihood that results from a specific
proposed study will influence policy, and the
nature of the likely policy change.
For two of the three case studies undertaken, the
model predicted the likely payback well, in that
the ex ante and ex post analyses both indicated
either clinical benefit or no clinical loss of benefit,
together with health services cost savings. The
result for the third case was inconclusive owing to
a very high (45%) level of non-compliance with
protocols, which meant that the potential benefits
of that research project were not realised and so
did not provide a test of the model. In the live
example given of an application of the model to
inform the decision whether a proposed study
should be carried out,71 the result appeared robust
and informed the decision not to fund a proposed
trial. It may be concluded that the model has a
valuable part to play in the research prioritisation
process, alongside existing criteria.
The strength of the PATHS approach is its
emphasis on the effect of possible outcomes of the
research on policy and/or practice, to an extent
that other models do not. It also has the
advantages of being transparent and open to
sensitivity analysis. Refereeing or reviewing
procedures for research proposals typically focus
on scientific merit, as judged by peer reviewers,
who are likely to be other academic researchers.
This tends to focus attention correctly on the
scientific criteria of validity, power and internal
consistency, and encourages researchers to use as
end-points measures or instruments that are well
validated and for which there are existing data on
which to base power calculations. However, where
policy makers respond to research outcomes with a
view to implementation, they may have very
different concerns, and be far more concerned
about the clinical or policy relevance and
importance of the outcomes measured. ‘Hard’
end-points such as mortality are likely to have
equal validity and relevance for researcher and
policy maker or commissioner alike. Softer end-
points, such as dimensions of the SF-36, may have
high validity and credibility with researchers, but
may have little resonance with policy makers,
compared with say cost or cost-effectiveness or
patient satisfaction. Ex ante modelling informed by
expert panels, as demonstrated here, not only can
help to identify where there is likely to be
substantial payback to research, but also may be
useful in indicating how the research design might
be improved to increase its chance of impacting
on policy and practice and so increase cost-
effectiveness. Equally, the process may help to
identify the most effective means of disseminating
knowledge of an ongoing trial and its results, to
facilitate implementation and change of 
practice.
The involvement of experts is a strength but also a
limitation to the model, and raises a number of
questions that could not be addressed directly. No
formal assessment was made of the optimal
combination of experts to consult or the effect of
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Conclusionsincreasing their number. We believe that the key
criterion is that they have sufficient detailed
expertise to have and to retain a realistic view of
what will change policy in the particular area of
interest. There was a considerable degree of
consensus between the experts, but in future
research it would be important to assess how
sensitive the results might be to reasonable
differences in expert opinion.
A number of important issues for payback have
been thrown up by the research. The UK NHS
R&D programme, among others, has set relevance
to the improvement of health and health services
as the keystone for research prioritisation for
which this model would be very appropriate.
However, if this is to be assessed it is very
important to know the baseline level of use of the
technologies or services being evaluated or
compared. This was not known or included in the
research proposals for any of the test cases,
although it was known for the live application.
Surveys and audits tend not to be valued in
research, although a case could be made that
survey data are an essential adjunct to a literature
review, for assessing the relevance and potential
importance of a health technology assessment. In
the NHS R&D system, such survey data, where
known, have usually formed an element of the
‘vignettes’ produced as part of the prioritisation
process. In these, such survey data are used to set
out the size of the problem, but often the detail
required is not available. Information on the
current use of a technology, and its expected
trajectory, is essential to the ex ante assessment of
payback. Payback cannot be evaluated without an
assessment of the counterfactual; that is, what
would happen regarding the use of the technology
if the research did not take place. Implications for
payback are very different for a new, as yet unused
technology that is likely to be adopted only if good
evidence is provided, compared with a technology
which, despite the lack of evidence, is in
increasing or widespread use. A large part of the
payback in the cases considered here was due to
an expected reduction in the use of the technology
if the research showed it to have low relative
benefit. Negative results may produce a high
payback. The process also requires explicit
consideration of the length of time over which the
research is likely to influence policy. This will
reflect a number of factors, such as the timing and
credibility of other studies, including international
studies, and likely changes to the technology or its
competitors. In an area of rapid technological
change, the policy relevance of research may be
quite transient.
The issue of equipoise is an interesting and ironic
one. There is a strong emphasis in the literature
on the need for equipoise as the ethical basis for
an RCT. However, the finer the state of equipoise,
the larger the study and the greater the risk of an
inconclusive result. An inconclusive result is likely
to give low returns to the research funding and
not to be a good use of resources, although there
is likely to be some gain in knowledge. A
conclusive result should lead to either an increase
in health benefit or a reduction in costs, and is
likely to repay the research costs unless these are
very high compared with the cost of using the
technology. Where the returns are assessed as
positive, the level of return will need to be
considered against returns to other competing
proposals in the prioritisation process. It is
unlikely that sufficient funds would be available to
fund all research with an acceptable incremental
cost-effectiveness ratio.
The model developed herein drew on existing
literature and approaches, particularly those
proposed by Weinstein,25 Eddy,22 and Townsend
and Buxton.16 Given the elapsed time since the
start of the project, it may be helpful to
recontextualise this work in the light of other
research published since the original literature
review. The literature search undertaken in May
1998 was repeated in January 2002, and it
identified 276 potential articles published in the
intervening period. Of these, only 12 appeared
possibly of direct relevance. Based on the full text
of these, three papers were found that had made
important contributions which, had they been
published earlier, would have figured significantly
in our consideration of the best methodology to
adopt. 
The first study is the work of Davies and
colleagues,93 which attempted a similar task to
that reported here. Davies and colleagues
attempted to apply a decision-analytical model,
based on their earlier work21 that was reviewed in
Chapter 2, to several topics considered by the UK
HTA programme in 1997 and 1998. Their
approach is in many ways similar to our own,
except that they focus entirely on the
consideration of a topic area, and do not consider
specific research proposals to study that topic.
Their approach attempts to provide a formal
overall prioritisation at an early stage in the
research commissioning sequence. They do not
attempt to address the question of the extent to
which a particular study will or will not be
convincing to policy makers. Their approach does,
however, recognise that policy and practice do not
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evidence, and it makes assumptions about the
level of likely uptake of the technology with and
without evidence of its effectiveness. It implicitly
assumes that all research has clear results, which is
not necessarily so, although it potentially allows
for the possibility of false-positive or false-negative
results. Davies and colleagues offer a guarded
conclusion that such an approach is feasible in
specific contexts, but needs further testing and
validation of results. 
Claxton and others have also taken forward earlier
proposals17,32,33 reviewed in Chapter 2, for
undertaking formal Bayesian ‘value of
information’ analyses to inform decision-makers
about the expected value of reducing uncertainty
about specific parameters in health technology
assessment contexts. This further work includes an
application that assesses the maximum value of
additional research in the context of the treatment
of Alzheimer’s disease.94 This work and other
Bayesian applications (e.g. by Fryback and
colleagues95 and Briggs96) are beginning to
demonstrate quite clearly the technical feasibility
of such analyses, although formal Bayesian
approaches remain opaque and inaccessible to
most decision-makers (see Sheingold97). They can
clearly provide important information and insights
concerning the design of major clinical trials and
economic evaluation studies, but are still currently
very demanding in terms of the scarce analytical
skills available to undertake them, and the sparse
understanding of the techniques by potential
users. Perhaps most importantly, they do not
consider the likely policy response to additional
information, but assume a totally rational model
of behaviour.
The third paper, by Meltzer,98 suggests alternatives
to the EVPI, including maximum value of
research, which are less demanding in terms of
knowledge of priors, and may offer a first stage
approach that deserves further consideration. 
Finally, to address the issue of the uncertain
impact of research on practice, Lilford and
colleagues,6 have suggested an approach to
research commissioning that involves potential
research users directly in the formulation of the
details of the research. They propose a method of
research in which the scope, form and content of
research on the delivery and organisation of
health services are developed iteratively by a
research director advised by a commissioning
group of health-service managers and research
commissioners. The aim is to provide flexibility in
responding to changing circumstances and, by
engaging potential users of the research in its
production, to enhance the likelihood of their
putting it to use. They emphasise that such
evidence as exists suggests that scientists need to
encourage decision-makers and be engaged by
them if the results of research are to impact on
practice. This form of involvement of users is
focused less on prioritisation of the ‘right’ topic
and more on ensuring that the research is
developed in ways that are most likely usefully to
inform policy and practice and which might,
taking the example used earlier, include the
relevance of alternative possible end-points with
relevance for policy. 
Recommendations to HTA
funders
The PATHS model demonstrated here offers a
conceptually simple approach to prioritising
research in terms of its overall likely net effect on
health benefits and costs of implementation, as
well as the costs of the assessment itself. It
considers the various likely outcomes of the
research and their probabilities. It features the use
of expert opinion from policy makers, clinicians
and academics to increase the relevance of the
assessment, and to supplement the knowledge of
the likely alternative outcome scenarios on policy
and implementation. It not only provides an
assessment of the cost-effectiveness of the
research, but may identify ways in which the
research design, end-points, analytical methods or
dissemination can be enhanced.
It is important that the type of analysis proposed
here be carried out by competent and impartial
evaluators and that it is transparent. The cost of
the sort of analyses that were used here is likely to
be between 1 and 4 weeks’ work for a researcher,
depending on the information available and the
complexity of the proposal. There may also be
costs of a small honorarium to the ‘expert’
clinician, manager or health economist for their
time. A total cost in the range or £1000 to £4000
per project or area is likely, possibly higher for
something large and complex. This would
represent a small proportion of the proposed
research cost and would be likely to give a good
return in terms of excluding low return proposals
or improving relevance and likelihood of
implementation. This is particularly true where an
outcome is likely to lead to a non-marginal change
in an expensive technology or to go against the
current trend. It may best be used after
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preliminary prioritisation has taken place and as
an important contribution to the final decision to
fund.
The authors recommend that formal analysis of
potential payback, along these lines, should be
undertaken as part of an ongoing evaluation for
projects costing over a certain threshold of, say,
£250,000. For very expensive projects, some
formal value of information analysis might also be
routinely appropriate. The cost of the process
demonstrated here, if undertaken routinely, would
be small in comparison to the cost of funding the
research. Whether a threshold were used or not,
the scale and intensity of the exercise could be
varied, to reflect the cost, perceived policy
importance and contentiousness of the proposal. 
Recommendations for further
research
Neither the PATHS model nor other current
models provide a complete solution to the
problems of prioritising topics and research
proposals. Together, they point towards possible
practical strategies and to a further research
agenda in which characteristics of all strategies
might be incorporated. Therefore, we think that
there is a high priority for research to synthesise
these approaches. 
This investigation was able to compare only
immediate ex post assessment of likely
implementation with the ex ante situation. Long-
term follow-up of actual implementation is
fundamental to formal testing of this approach
and research is needed in this area.
Expert opinions have a key role to play in the
model and research is required to assess how
robust the approach is to the choice and number
of experts.Health Technology Assessment 2003; Vol. 7: No. 20
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G
iven the broad area and the variety of possible
search terms, the aim of the search was to
achieve higher sensitivity rather than specificity. 
Strategy used to search MEDLINE:
1 (priorit$ adj3 setting).ti.
2 (research adj5 priorit$).mp. 
3 (economi$ or cost$1 or fund$ or financ$).mp. 
4 (preliminary adj5 apprais$).mp. 
5 ((assess$ or select$ or plan$ or evaluat$) and
(biomedical or medical or health) and
(research or trial or technolog$)).mp. 
6 (model$ or “decision analy$” or scenario).mp. 
7 “expected value of information”.mp.
8 1 and 5
9 (1 and 2) not 8
10 4 not (8 or 9)
11 3 and 5
12 6 and 11
13 (priorit$ or payback or return).mp. and 12 
14 (priorit$ or payback or return$).mp. 
15 2 and 14
16 7 or 8 or 9 or 10 or 13
17 (3 and 5 and 6) not 16
18 ((assess$ or select$) and (health or biomedical
or medical) and (research or trial or
technology)).mp. 
19 (3 and 6 and 18) not 16
20 1 and 6
21 16 not 19
22 “value of information”.mp. 
23 18 and 22
24 6 and 22
25 2 and 3 and 6
26 19 and (priotit$ or payback or return$).mp.
27 algorithms/ or knowledge/ or methods/ or
models, theoretical/ or research/ or clinical
protocols/ or pilot projects/ or research design/
28 2 and 6 and 27
29 health care rationing/ or health care reform/ or
health plan implementation/ or health
planning guidelines/ or health priorities/ or
health services research/ or national health
programs/ or technology assessment,
biomedical/
30 2 and 6 and 29
31 27 and 6 and 2 and 3 and 29
32 3 and 6 and 14
33 Research Design/
34 Decision Making/
35 32 and (33 or 34)
36 20 not 35
37 19 and (health or research or priorit$).mp. 
38 35 or 36 or 37 or 7
39 (2 and 3) not 38
A similar search strategy was used for
HealthSTAR.
The yield of the search was 707 papers, while a
further 319 were identified in the updating search,
which covered the period 1999 to early 2002.
  HEED
Search strategy:
1. research AND priorit*
2. fund* OR financ* OR cost OR assess
3. research OR health OR biomedical
4. preliminary OR payback OR priorit*
5. 2 AND 3 AND 4 NOT 1 
In 1998 the search yielded 249 references and a
further 38 references were produced in the
updating search.
  BIDS IBSS:
Search all types of publications in English in the
fields of Economics, Sociology and Political
science. 
Search for: research AND priorit* in
Title/keywords/abstract
BIDS produces 72 hits and another 97, published
after 1998.
Appendix 1
Details of the search strategyHealth Technology Assessment 2003; Vol. 7: No. 20
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A synopsis of the trial is given on the last page of this appendix.
Appendix 2
Trial of the costs and benefits of postnatal 
midwifery support
Background
Enclosed are several papers and articles which provide information concerning the background to the
research project ‘The Costs and Benefits of Post-natal Midwifery Support’, and to the intervention
itself. The researchers have agreed for this trial to be a case study for our model which will be
informed by your opinions below. As you know, we are developing a model for the NHS HTA R&D
programme to assess the likely costs and benefits of undertaking specific research proposals. The
model will attempt, among other things, to estimate the ‘expected cost-effectiveness ratio’ of a research
proposal.
Within the model we will include the cost of the trial and the likely costs associated with
implementation. The latter will depend upon current and likely future practice as well as the outcome
of the trial itself.
Likely cost of the service
The direct cost of one Community Midwifery Support Worker (CMSW) is about £10,820 per year, of
which £10,375 is salary costs (direct costs are therefore heavily dominated by the salary). The direct
cost to a Health Authority of providing a comprehensive CMSW service depends upon the fertility rate
in the geographical area. Using data from the 1995 Birth Statistics, the mean number of maternities in
a health authority in 1995 was 6114 (SD 2454), with the median being 6087 (range 1227–15,057). If a
CMSW can make three visits a day, five days a week, and each mother receives 10 daily visits within the
first 28 days, on average a CMSW will visit approximately 6 mothers per month. Therefore, using a
crude calculation, the direct cost to a health authority of a CMSW service will be approximately
£150,000 for every 1000 births, or £150 per birth.
There may also be changes in the use of other personal health and social services by the mother and
child. These may increase or decrease. Included with this paper are several journal articles relating to
the use of health services by mothers in the early postpartum period. Your opinion as to the likely
change in the use of health services (in particular GP visits) if any, would be welcome. In particular
whether you think the utilisation of other services might increase or decrease (and if so which services
and by how much).
Possible trial conclusions
In order to perform a preliminary economic evaluation to estimate the expected returns to the
research, estimation is also needed of the likely benefits from the implementation of the technology.
This information will come mainly from the outcome of the trial. We will ask you to consider three
likely conclusions of the trial, and how Health Authorities or Trusts might implement this service
accordingly. The extent of the implementation of a CMSW service would also be important. The trial
evaluates a service for all mothers in the early postpartum period. However, it is possible that certain
Health Authorities or providers might consider introducing the service for selected ‘at risk’ groups.Appendix 2
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Questions to experts
We should like to meet you to discuss the issues surrounding this research project. Below are the areas
which we would like to discuss with you in the light of the enclosed papers, the research proposal briefing
and given your own expert knowledge and experience. (Please contact us if you have questions prior to
our meeting).
Local postnatal service
The level of implementation of the CMSW service is also likely to vary according to existing services,
as the provision of postnatal care currently varies considerably across different localities, especially with
regard to the number of midwife visits; current provision of services will affect the ease with which a
Support Worker service may be introduced into an area.
It might help to consider your answers in the light of alternative levels of existing services:
Local policy A
Provision of postnatal care by midwives follows approximately the national policy of not less than ten
daily midwife visits.
Local policy B
Selective visiting based upon the midwife’s judgement regarding needs of the mother.
The following pages will make reference to these alternative local policies.
Question 1: The development of postnatal services
Given the organisation of postnatal care around 1994 (the time of the research proposal), what
structure and level of service would you have expected now? The paper by Garcia, Renfrew and
Marchant (1994)49 identified patterns of postnatal care in the early 1990s. Do you think this pattern
would have continued, or would you have expected some reform?
There are three potential conclusions to the trial:
• favourable (i.e. implementation of the experimental intervention is encouraged)
• unfavourable (i.e. implementation of the experimental intervention is discouraged)
• inconclusive (i.e. the trial fails to arrive at a significant conclusion, or there is no clear difference in
cost-effectiveness).
Our questions seek your opinion regarding the likely future practice given these broad conclusions,
and the costing information presented above.
Question 2: Implementation of the intervention following reports of the trial
results
This section will cover how postnatal services may develop following the conclusion and reporting of
the trial. The areas which we wish to cover for each of the three potential conclusions of the trial, 
i.e.:
  Favourable (a significant difference in self-reported health status in favour of the new intervention
with a favourable cost-effectiveness ratio for the CMSW service)
  Unfavourable (a significant difference in self-reported health status against the new intervention
with an unfavourable cost-effectiveness ratio for the CMSW intervention)Health Technology Assessment 2003; Vol. 7: No. 20
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  Inconclusive (no significant difference in self-reported health status and the cost between the
control and the new intervention).
are:
1. To what extent, if any, might (or would you recommend) this new service be adopted – what
percentage of midwifery services might introduce a CMSW service?
2. How might the existing local policy regarding the provision of midwifery services affect the level of
implementation? (e.g. related to the alternatives local policies on page 2).
3. If implemented, might you expect or recommend the service be provided to all women, or targeted
at certain ‘at risk’ groups?
Question 3: Effects on the use of other services
If the CMSW service were adopted, how might other relevant health services be affected, specifically:
  midwifery services (if released because the CMSW service reduced the need for midwifery visits)
  GP services.
(consider in the light of the alternative current policies given on page 2).
Question 4: Outcome measures used in the trial
Do you think that the major and other outcome measures used by the researchers are the appropriate
ones for the research? Which might be more likely to influence policy and/or practice (SF-36 general
health perception dimension, Edinburgh Postnatal Depression Index, breast-feeding rates, SF-36
health status)? Are there alternative outcome measure(s) you think would be more appropriate?
Question 5: Threshold levels
The primary end-point in the researchers’ cost-effectiveness analysis is a five-point improvement in the
General Health Perception dimension of the SF-36. This dimension covers five questions:
1. In general, would you say your health is
  Excellent
  Very good
  Good
  Fair
  Poor
11a. I seem to get ill more easily than other people 11c. I expect my health to get worse
  Definitely true   Definitely true
  Mostly true   Mostly true
  Don’t know   Don’t know
  Mostly false   Mostly false
  Definitely false   Definitely false
11b. I am as healthy as anybody I know 11d. My health is excellent
  Definitely true   Definitely true
  Mostly true   Mostly true
  Don’t know   Don’t know
  Mostly false   Mostly false
  Definitely false   Definitely falsePostnatal care: references
Garcia J, Renfrew M, Marchant S. Postnatal home
visiting by midwives. Midwifery 1994;10:40–3.49
Glazener C, Abdalla M, Russell I, Templeton A.
Postnatal care: a survey of patients’ experiences.
British Journal of Midwifery 1993;1:67–74.50
Twaddle S, Liao XH, Fyvie H. An evaluation of
postnatal care individualised to the needs of the
woman. Midwifery 1993;9:154–60.51
Van Teijlingen ER. The profession of maternity home
care assistant and its significance for the Dutch
midwifery profession. Int J Nurs Stud
1990:27:355–66.52
Synopsis: the costs and benefits
of postnatal midwifery support
Sample 
  All women delivering a live baby after 37+
weeks of gestation, birth weight 2.5 kg+. 360
women in each group.
Intervention
  Midwifery visit on days 1 (or discharge day), 3
(or 4), 6 and 10
  Community Midwifery Support Worker (CMSW)
visit daily on weekdays (10 visits)
  24 hour telephone access to midwife until the
28th day
  CMSW will be managed within the provider
Trust (Northern General Hospital), trained to
NVQ level 2, and will work to protocols and
guidelines for a narrow range of tasks, i.e.
establish a supportive relationship, provide
regular contact to recognise signs of problems,
reinforce midwifery advice regarding breast
feeding, etc., do light housework and encourage
appropriate use of health services and other
agencies.
Control
  Current midwifery visiting practice until the
28th day
  24 hour telephone access to midwife until the
28th day
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The trial is set to identify a five-point improvement in General Health Perception. This would be
achieved by the mother moving up one score in one answer with the answers to the other questions
remaining the same. For example, if the answer in 11b went from ‘don’t know’ to ‘mostly true’, and all
other answers remained the same, this would be approximately equivalent to a five-point
improvement. This is the minimum improvement that the trial would detect. The actual improvement
detected could of course be much higher.
We are interested in the level of cost-effectiveness that might trigger adoption of this intervention.
Would you have some feel for how much a commissioner of postnatal services might be willing to pay
to achieve an improvement? Alternatively, how much of her budget would a Director of midwifery
services in a provider trust be willing to allocate per woman to achieve an improvement of so many
points (e.g. 5, 15, 25 points)? Do you think there are other services that would be worth dropping to
achieve this?
Use of answers from experts
We shall run a series of preliminary economic evaluations using this information, the cost of the trial
and the expected cost of implementation to determine the cost-effectiveness ratio. Your answers to the
questions on the likely implementation of the intervention following the trial and the effects on other
health services will be used to help estimate the expected costs and benefits from the likely
implementation of the CMSW service. These preliminary economic evaluations will then be used for a
‘mock report’, designed to inform a research funding body on the likely returns to the research. This
will be compared with the actual results when they are published, using predictors of the impact of the
results.
Thank you very much
We should like to come back for your further predictions when the actual results of the trial are
available.Health Technology Assessment 2003; Vol. 7: No. 20
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End-points
Major (basis for sample size):
  SF-36 GHP score at 6 weeks (trial size to detect
five-point difference between groups, 5%
significance, 80% power).
Other end-points:
  6 weeks: Edinburgh Postnatal Depression
Inventory, SF-36 health status, breast feeding
  6 month follow-up: SF-36, breast feeding,
maternal morbidity, acceptability of service,
additional use of health and other services in
first 6 months.
Economic analysis
  To establish additional (or reduced) cost
incurred by the intervention over the control,
related to the benefits of the expected
intervention. Cost-effectiveness in terms of cost
per five-point improvement in health measure
on SF-36 GHP dimension (direct and indirect
costs, fixed and variable costs).
Other information collected 
(at 6 weeks and 6 months)
Mother’s feeling for baby, confidence, control and
self-esteem, information and advice received,
support from family/friends/professionals,
acceptability of care.Health Technology Assessment 2003; Vol. 7: No. 20
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All answers are completely confidential
Given the attached results of the trial of costs and benefits of the community postnatal support worker
service53
1. To what extent, if any, might or would you recommend that this service now be adopted:
For all women?
For certain ‘at risk’ groups?
For no women?
Over what timescale do you think this change if any would be implemented?
Comments
2. Were such a service in use, as it is in certain areas, would you recommend it be:
Reduced?
Terminated?
Over what timescale do you think this change be implemented?
Comments
Appendix 3
Trial of the costs and benefits of postnatal 
midwifery support: questions to experts (2)70
3. Which of the outcome measures do you think were relevant to your decision? (Mark 1, 2 … in order of
preference)
SF-36 General Health Perception dimension
Edinburgh Post Natal Depression Score
Breast-feeding rates
SF-36 health status
Client satisfaction with service
4. Are there any means of dissemination you think necessary to speed any desired change?
5. Any overall comments on the study and/or the results
Appendix 3Health Technology Assessment 2003; Vol. 7: No. 20
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Appendix 4
An RCT of infusion protocols in adult 
pre-hospital care
Background
Enclosed are several papers and articles which provide information concerning the background to the
research project ‘An RCT of Infusion Protocols in Adult Pre-Hospital Care’, and to the intervention itself.
The researchers have agreed for this trial to be a case study for our model, which will be informed by
your opinions below. As you know, we are developing a model for the NHS HTA R&D programme to
assess the likely costs and benefits of undertaking specific research proposals. The model will attempt,
among other things, to estimate the ‘expected incremental cost-effectiveness ratio’ of a research
proposal.
Within the model we will include the cost of the trial and the likely costs associated with
implementation, which will depend upon current and likely future practice according to the outcome
of the trial.
Possible trial conclusions
In order to perform a preliminary evaluation to estimate the expected returns to the research,
estimation is needed of the likely benefits from the implementation of the technology. This
information will come mainly from the outcomes of the trial, which as yet are of course unknown. We
will ask you to consider three possible conclusions of the trial, and how ambulance services might
implement this service accordingly. Implementation of particular protocols would also be important.
The trial evaluates the benefits of ‘scoop and run’ compared with ‘field stabilisation’ for trauma
patients whose estimated time of transport to hospital is between 15 and 60 minutes. 
Therefore, there are three different potential conclusions to the trial:
  Favouring ‘field stabilisation’ for patients by using a crystalloid and colloid mixture (protocol A).
  Favouring ‘scoop and run’ (protocol B).
  Inconclusive (i.e. the trial fails to arrive at a significant conclusion, or there is no clear difference in
cost-effectiveness between using a ‘scoop and run’ protocol and a ‘field stabilisation’ protocol).
Differences in patient management between the two protocols will occur during transport to
hospital, although the cost implications of this are likely to be minimal. However, differences in
patient management might also occur in the A&E department, the relevant inpatient departments
and in the primary and community care setting. These will produce cost differences. These
differences could be due to the lower costs of patients recovering more quickly after on-scene i.v.
infusion, or perhaps, greater costs due to the use of i.v. infusion saving more lives, which
subsequently may increase the number of seriously disabled survivors.Aim
The study aims to evaluate the use of cannulation
and fluid infusion at the accident scene (field
stabilisation) by ambulance personnel in severely
injured adults, compared with the immediate
transport to hospital (scoop and run).
Sample
Includes: adult trauma patients attended by East
Anglia and Leicestershire ambulance and
paramedic services, who:
  subsequently stayed in hospital for 72+ hours,
or died as a result of their injuries OR
  had a triage-revised trauma score of 10 or less
on scene.
Excludes: those attended by a doctor on scene,
those who were transported by helicopter, those
patients who died or had a revised trauma score of
0 on scene and did not show any signs of life
during pre-hospital phase (poisonings, hangings,
drownings and asphyxiations).
Study design
420 paramedics will be randomised to work
according to one of two protocols if the estimated
time of transport of a trauma patient to hospital is
between 15 and 60 minutes (see attached).
  Protocol A: Leans to field stabilisation (infusion
by colloid/crystalloid combination if any of the
indicators given in the current operational
protocols for i.v. infusion are present).
  Protocol B: Leans to ‘scoop and run’ (infusion
only if time to hospital is greater than 60
minutes).
It is estimated that the two ambulance services will
yield over 1600 patients over one year, or 3.8
patients per paramedic. 
The trial is set to detect a difference in mortality
of 14% versus 20% between the two arms of the
trial (significant at the 5% level and 80% power).
Outcomes
Mortality, length of stay in hospital, length of stay
in intensive care, broad disability level and general
health status at two and six months after injury.
a) Overall mortality is compared for blunt
trauma patients whose estimated time of
arrival at the hospital is 15–60 minutes.
b) all adult trauma patients meeting the
inclusion criteria attended by paramedics in
the two main arms of the study, after
standardising for case-mix (i.e. however long
to hospital).
Morbidity: comparisons of disability on discharge
and SF-36 scores in the two groups, adjusted for
case-mix.
Subgroups: analysing outcomes by time since
training and by years of experience of the
paramedics.
Economic analysis
The estimated marginal cost of operating the
infusion protocol will be related to the benefits in
terms of reduced fatality and/or disability. The
implied marginal cost of life years saved and
reduced fatality with similar implied values as
obtained from other health service interventions,
will be compared with the estimated marginal cost
of the infusion protocol.
Questions to experts
Appendix 4
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Likely future practice
1. How would you have expected (in 1995) the
provision of A&E pre-hospital services to
have developed in the absence of this trial?
In particular, would you have expected that
the trend to ‘field stabilisation’ would have
continued generally, or would this have been
the case only for patients with specific
injuries or conditions?
Possible trial outcomes
2. Given the following possible outcomes of the
trial:
  Favouring scoop and run.
  Favouring field stabilisation.
  Inconclusive
What would you expect to be the likely change
in practice? In particular, what proportion of
ambulance services would you expect to
introduce such a protocol? Health Technology Assessment 2003; Vol. 7: No. 20
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Trial outcomes 
3. The outcome measures are a range of measures relating to mortality and morbidity in hospital and
in the community over 6 months (mortality, length of stay in ITU, broad disability level, general
health perception using SF-36 at 2 and 6 months after injury). 
Do you think these are the most appropriate outcomes? Which might be more likely to influence
future policy and practice in the provision of pre-hospital care to adult trauma patients? Are there any
other outcomes that might have been relevant, or more relevant than those used?
Threshold levels
4. The study is designed to detect a difference in mortality of 14% versus 20% between the two arms
of the trial (80% power, significant at 5%). Given that there are approximately 650 adult trauma
patients per annum in a non-metropolitan area covered by one ambulance service, if this minimum
(6%) difference were detected, at least 41 extra patients would survive per year (about one-third
fewer deaths) under the more effective protocol. 
The economic evaluation will present the relative cost-effectiveness in terms of the marginal cost of
following the infusion protocol related to marginal benefits in terms of reduced mortality and/or
disability. 
We are interested to know what barriers, if any, you think might prevent the adoption of what is found
to be the more effective service. 
  What sort of financial barrier might there be to the adoption?
  What sort of cost-effectiveness barrier might there be? (i.e. how big would the benefits need to be
relative to the costs?)
  Might there be other barriers to adoption, e.g. organisational barriers?
We are interested to know what level of incremental costs you think would be too high for the more
effective strategy to be adopted by an ambulance service, given that for an average ambulance service
at least 41 more patients would be expected to survive (about one-third fewer deaths) under the more
effective protocol. It might be useful to give your answer as a percentage of the annual ambulance
service budget.
Probabilities of trial outcomes
5. There are three potential outcomes for the trial:
  Favouring scoop and run.
  Favouring field stabilisation.
  Inconclusive.
We should like to know what you think are the most likely outcomes of the trial. Could you assign
percentages to the likelihood of the trial reaching each of the three outcomes listed above, from 0%
(no chance) to 100% (absolute certainty)? The sum of all three should come to 100%.Appendix 4
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A&E fluid infusion protocol:
references
British papers
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shock. Eur J Emerg Med 1994;1:83–5.56
US papers for or against field
stabilisation
Aprahamian C, Thompson BM, Towne JB, Darin JC.
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major open intra-abdominal vascular trauma. 
J Trauma 1983;23:687–90.57
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1994;1:31–3.61
Use of your answers
We shall run a series of preliminary economic evaluations using this information, the cost of the trial
and the expected cost of implementation, to determine the cost-effectiveness ratio. Your answers to the
questions on the likely practice following the trial’s conclusion and the effects on other health services
will be used to help estimate the expected differences in costs and benefits of an ambulance service
implementing a field stabilisation protocol, compared with those of a scoop and run protocol. These
preliminary economic evaluations will then be used for a ‘mock report’, designed to inform a research
funding body on the likely returns to the research. This will be compared with the actual results when
they are published, using predictors of the impact of the results.
Thank you very much
We should like to come back for your further predictions when the actual results of the trial 
are available.Health Technology Assessment 2003; Vol. 7: No. 20
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All answers are completely confidential
Given the attached results of the trial of infusion protocols relating to adult trauma patients whose
estimated time of transport to hospital is between 15 and 60 minutes:63
1. What change in practice, if any, do you think will result from the results of the trial?
What proportion of services would now use the ‘scoop and run’ protocol for these patients?
What proportion of services would now use the ‘field stabilisation’ protocol for these patients?
2. Over what timescale do you think the change, if any, would take place?
Appendix 5
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3. What means of dissemination or other action do you think would be effective in speeding any
appropriate change?
4. Which of the outcome measures were relevant for your views on practice change in the previous
questions?  (mark 1, 2 … in order of importance)
Mortality
Length of stay in ITU
Broad disability level
General Health Perception using SF-36 at 2 months after injury
General Health Perception using SF-36 at 6 months after injury
5. Any overall comments on the study and/or results?
Appendix 5Aim
The study aims to compare the mortality, quality
of life and health-service costs associated with
early surgical repair compared with surveillance in
the management of small abdominal aortic
aneurysms.
Sample and study design
Patients aged 60–76 years with asymptomatic
abdominal aortic aneurysms (4–5.5 cm) will be
recruited from referrals to the participating
vascular surgeons and coordinated from five
centres. More than 120 vascular surgeons will
participate in the trial and 1000 patients will be
recruited, 500 in the first year and 250 in each
successive year of the project. Patients will be
followed up for an average of 5 years each,
making 5000 patient years of follow-up.
Outcomes
Mortality: all-cause mortality at 2, 4 and 6 years
will be compared between the surgical repair and
surveillance groups.
Quality of life: measured by the Medical Outcomes
Study short-form general health survey prior to
randomisation, and every 3 months or 6 months
(depending on size of aneurysm) for the duration
of observation, or 1 year after surgical repair.
Health Technology Assessment 2003; Vol. 7: No. 20
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Appendix 6
The UK small aneurysm trial
Introduction
As you know we are developing a model for the NHS HTA R&D programme to assess the likely costs
and benefits of undertaking specific research proposals. The model will be used among other things,
to estimate the ‘expected cost-effectiveness ratio’ of a research proposal.
To apply the model we will need to use the cost of the trial and the likely costs associated with
implementation. The latter will depend upon current and likely future practice as well as the outcome
of the trial itself. 
Enclosed are several papers and articles that provide information concerning the background to the
research project ‘The UK Small Aneurysm Trial’. The researchers have agreed for this trial to be a case
study for our model, which will be informed by your opinions below.
Background to the study
The study consists of a number of separate proposals that together form the UK Small Aneurysm
Trial. Our study will consider the trial as a whole, and not the individual components.
This trial is designed to determine whether early elective surgery as compared with a period of
ultrasound surveillance provides better management of patients with small abdominal aortic
aneurysms (4.0–5.5 cm in diameter). The study is a multicentre randomised trial, including
approximately 1000 patients aged 60–76 years, randomised to either surgery or ultrasonographic
surveillance. 
The study will compare long-term survival over 5 years and the costs between the surgery and
surveillance groups. Health-related quality of life will also be compared between the two groups.Appendix 6
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Economic analysis
The costs to the NHS of the two alternative management protocols will be compared, and used in
conjunction with the mortality results and the quality of life comparisons to make recommendations on
the management of small asymptomatic abdominal aortic aneurysms.
Questions to experts
Possible trial conclusions
We should like to ask you to consider three possible conclusions of the trial, and make an informed
guess at how NHS Trusts, relevant departments or consultants, might, for each conclusion, adjust their
treatment of patients with small abdominal aortic aneurysms.
There are three potential conclusions to the trial:
  Favouring surgery (improved mortality for surgery compared with surveillance, favourable balance
with quality of life and cost-effectiveness, significant difference in cost-effectiveness and improved
quality of life in comparison to patients under surveillance).
  Favouring surveillance of patients (no significant improvement in mortality after surgery, favourable
balance of quality of life between surgery and surveillance and a preferable cost-effectiveness ratio
for surveillance).
  Inconclusive between surgery and surveillance (where neither of the scenarios above dominates, e.g.
no clear difference in the cost-effectiveness ratio, taking into account mortality, quality of life and
costs).
We would like your opinion regarding future practice under each of the three scenarios (see over).
Likely future practice
1. To assess the effect of the proposed trial on practice, we need to have some idea of how practice
would have developed in the absence of this trial. The initial proposal was submitted in 1990.  How
would you have expected  (in 1990) the treatment of patients aged 60–76 with small abdominal
aortic aneurysms to have developed? What proportion of patients with small aneurysms would have
undergone early elective surgery in 1990, and how would this have developed over the subsequent
10 years if this trial had not proceeded?
Possible trial outcomes and implementation
2. Given each of the following possible scenario outcomes of the trial, as defined on the previous
page:
  Favouring surgery
  Favouring surveillance
  Inconclusive between surgery and surveillance
What would you expect to be the likely development of management following each of these
conclusions? In particular, what proportion of cardiovascular surgeons or NHS trusts would employ
the more effective and/or cost-effective management procedure?
How might practice change if the trial reached the ‘inconclusive’ outcomes?Health Technology Assessment 2003; Vol. 7: No. 20
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Trial outcomes
3. The primary outcome measure used in the trial is all cause mortality over 5 years. A secondary
measure is health-related quality life as measured by the Medical Outcomes Study short-form
general health survey. Quality of life is measured prior to randomisation and every 3 months or 6
months (depending on the size of the aneurysm) for the duration of ultrasonographic surveillance,
or 1 year after aneurysm repair. Health-service costs were also measured as part of the trial
outcome.
Do you think that these are the most appropriate outcome measures? Are there any other outcomes
that might have been relevant, or more relevant than those used?
Threshold levels
4. The study is designed to detect a 5 year difference in mortality of at least 9% with 80% power,
significant at 5% between the two arms of the trial (e.g. a 5 year mortality associated with surgery of
29% with 38% in the surveillance group). In addition, surgical repair may be associated with a
higher level of quality of life. What combination of improved mortality and improved quality of life
and increased costs would be acceptable to surgeons or NHS trusts to trigger a change in practice?
We are interested to know what barriers and threshold levels might exist concerning the adoption of
the more cost-effective management protocol:
  What reduction in mortality due to surgical repair would be sufficient to persuade vascular surgeons
to change from observation to early surgical repair?
  What sort of financial barrier might there be to the adoption? Specifically, if the minimum
detectable reduction in mortality of 9% due to surgical repair were found to be significant, what
level of net incremental cost associated with surgery might prevent the adoption?
  What level of improvement in quality of life (percentage improvement in the Medical Outcomes
Study short-form general health survey score), if any, would be sufficient to encourage the early
surgical repair of aneurysms, if the incremental cost per patient was:
(1) £100
(2) £500
(3) £1000
(4) £1500
(5) £2000?
Probabilities of trial outcomes
5. There are three potential outcomes for the trial (defined on page 1):
  In favour of surgical repair.
  In favour of ultrasonographic surveillance.
  Inconclusive between surgery and surveillance.
What do you think is the most likely outcome of the trial?  Could you assign percentages to the
likelihood of the trial reaching each of the three outcomes listed above, from 0% (no chance) to 100%
(absolute certainty)? The sum of all three should come to 100%.Appendix 6
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UK small aneurysm trial:
references
Bengtsson H, Bergqvist D, Jendteg S, Lindgren B,
Perrson U. Ultrasonographic screening for abdominal
aortic aneurysm: analysis of surgical decisions for
cost-effectiveness. World J Surg 1989;12:266–71.64
Cheatle TR, Scurr JH. Abdominal aortic aneurysms: a
review of current problems. Br J Surg
1989;76:826–9.65
Collin J, Araujo L, Walton J, Lindsell D. Oxford
screening programme for abdominal aortic aneurysm
in men aged 65 to 74 years. Lancet 1998;ii:613–15.66
Quill DS, Colgan MP, Summer DS. Ultrasonic screening
for the detection of abdominal aortic aneurysms. Surg
Clin North Am 1989;69:713–20.67
Implications for national screening programme
6. What possible implications, if any, do you think the possible different outcomes would have for a
national screening programme?
Use of expert answers
We shall run a series of preliminary economic evaluations using the cost of the trial and the expected
cost of changed management to determine the cost-effectiveness ratio.  Your answers to the questions
on the likely changed management or otherwise for each scenario outcome of the trial will be used to
help estimate the expected costs and benefits from the trial.  These preliminary economic evaluations
will then be used for a ‘mock report’, designed to inform a research funding body on the likely returns
to the research.  This will be compared with the actual results when they are published, using
predictors of the impact of the results.
Thank you very much
We should like to come for your further predictions when the actual results of the trial are available.Health Technology Assessment 2003; Vol. 7: No. 20
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All answers are completely confidential
Given the attached results68,69 of the UK small aneurysm (size 4.0–5.5 cm for patients aged 60–76) trial:
1. In your judgement, what proportion of cardiovascular surgeons would now treat such aneurysms 
With surgery?
With ultrasonic surveillance?
2. Do you think there would be likely difference in choice of treatment within these ranges according to
age or size of aneurysm?
Detail
3. Which of the outcome measures were relevant to your judgement? (Mark 1, 2 … in order of
importance)
All cause mortality over 5 years
Quality of life on Medical Outcome Study Health Survey
Health services costs
Appendix 7
The UK small aneurysm trial: questions to 
experts (2)82
4. Do you think these results may change treatment for patients outside the ranges of the study?
5. What implications do you think the results have for a possible national screening programme?
6. What means of dissemination of the results or other action do you think is necessary for appropriate
implementation?
7. Any overall comments on the study and/or the results?
THANK YOU VERY MUCH
Appendix 7Health Technology Assessment 2003; Vol. 7: No. 20
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Feedback
The HTA Programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website
(http://www.ncchta.org) is a convenient way to publish 
your comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.